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ABSTRACT
Irrespective of plentiful efforts to enhance primary prevention and early detection, the number of
melanoma cases in the United States has increased steadily over the past 30 years, thus greatly
affecting public health and the economy. We have investigated the effects of five novel aPKC
inhibitors; 2-acetyl-1,3-cyclopentanedione (ACPD), 3,4-Diaminonaphthalene-2,7-disulfonic acid
(DNDA), [4-(5-amino-4-carbamoylimidazol-1-yl)-2,3-dihydroxycyclopentyl] methyl dihydrogen
phosphate (ICA-1T) along with its nucleoside analog 5-amino-1-((1R,2S,3S,4R)-2,3-dihydroxy4-methylcyclopentyl)-1H-imidazole-4-carboxamide

(ICA-1S)

and

8-hydroxy-1,3,6-

naphthalenetrisulfonic acid (ζ-Stat) on cell proliferation, apoptosis, migration and invasion of two
malignant melanoma cell lines compared to normal melanocyte cell lines. Molecular docking data
suggested that both ACPD and DNDA specifically bind to protein kinase C-zeta (PKC-ζ) and
PKC-iota (PKC-ι) while both ICA-1 compounds specifically bind to PKC-ι, and ζ-Stat showed a
high affinity towards PKC-ζ. Kinase activity assays were carried out to confirm these observations.
Results suggest that PKC-ι is involved in melanoma malignancy than PKC-ζ. Both isoforms
promote the activation of nuclear factor (NF)-κB and protein kinase B (AKT) thereby supporting
survival and progression. In addition, we demonstrated that PKC-ι induced the metastasis of
melanoma cells by activating Vimentin, and PKC-ι inhibition downregulated epithilialmesencymal transition (EMT), while inducing apoptosis. Of note, PKC-ἱ specific inhibitors
downregulated the expression of both PKC-ι and phosphorylated PKC-ι, suggesting that PKC-ι
plays a role in regulating its own expression in melanoma. We also report the underlaying
mechanisms of the transcriptional regulation of PKC-ι (PRKCI gene) expression in melanoma. cxiii

Jun, interferon-stimulated gene factor 3 (ISGF3), paired box gene 3 (PAX3), early growth response
protein 1 (EGR1) and forkhead box protein O1 (FOXO1), which bind on or near the promoter
sequence of the PRKCI gene, were analyzed for their role in PKC-ι regulation in SK-MEL-2 and
MeWo cell lines. We silenced selected transcription factors using siRNA, and the results revealed
that the silencing of c-Jun and FOXO1 significantly altered the expression of PRKCI. The levels
of both phosphorylated and total PKC-ι increased upon FOXO1 silencing and decreased upon cJun silencing, suggesting that c-Jun acts as an upregulator, while FOXO1 acts as a downregulator
of PRKCI expression. We also used a multiplex ELISA to analyze multiple pathways other than
NF-κB that were affected by treatment with PKC-ι inhibitor. The silencing of NF-κB p65 and
PKC-ι by siRNA suggested that the regulation of PKC-ι expression was strongly associated with
FOXO1. In addition, we observed a significant decrease in the mRNA levels of both interleukin
(IL)-6 and IL-8, with a significant increase in the levels of IL-17E and intercellular adhesion
molecule 1 (ICAM-1) upon the knockdown of expression of PKC-ι in both cell lines. This
suggested that PKC-ι expression was affected by these cytokines in an autocrine manner. Overall,
the findings of this study suggest that PKC-ι inhibition suppresses its own expression, diminishing
oncogenic signaling, while upregulating anti-tumor signaling, thus rendering it an effective novel
biomarker for use in the design of novel targeted therapeutics for melanoma.
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CHAPTER 1
PROTEIN KINASE C

1.1 Introduction
Cells have strict regulatory mechanisms to maintain normal behavior and perform desired
functions. Protein kinase C (PKC) is a superfamily of various protein kinase enzymes that are
important for the phosphorylation of serine and threonine amino acid residues on other proteins
and thereby play several critical roles in cellular signal transduction cascades. Yasutomi
Nishizuka, a well-known biochemist, discovered the first PKC isoform in 1977 (1). During his
studies of PKC function, he discovered novel intracellular signal transduction systems and
elucidated the PKC regulatory mechanisms involved in many biological processes (2). Nishizuka
et al. found that PKC can be activated by calcium ion (Ca2+) dependent proteases such as Calpain,
co-factors such as diacylglycerol (DAG) and phosphotidylserine (PS). Over the span of three
decades numerous isoforms of PKC with different activation processes have been discovered (1–
4).

1.2 PKC isoforms and classification
The PKC superfamily currently contains sixteen isoforms in Homo sapiens (5). Depending on the
second messenger requirements for the activation, these isoforms are classified into three main
1

subclasses with two additional related groups. They are conventional (or classical), novel, and
atypical. Isoforms alpha (α), beta I (βI), beta II (βII) and gamma (γ) occupy the conventional
(c)PKC class. They require Ca2+, DAG, and PS for activation. Novel (n)PKCs are comprised of
isoforms delta (δ), epsilon (ε), eta (η), and theta (θ). nPKCs require DAG and PS but are
independent of Ca2+ ions for activation. The atypical (a)PKC class contains iota (ι) and zeta (ζ).
aPKCs are independent of DAG and Ca2+ but require PS for the activation. Apart from these 3
subclasses, protein kinase D (PKD), another family of serine/threonine protein kinases, is
considered as a subfamily of PKC, contains three isoforms PKD1, PKD2 and PKD3 (6). PKC
related kinases (PK-Ns) are also considered as a subfamily of PKCs and contains 3 isoforms (PKN1, PK-N2 and PK-N3) (7,8). The structural differences among subclasses are discussed in part
1.3.

1.3 Protein Kinase C structure
All the members of the PKC superfamily share a largely conserved carboxyl-terminal catalytic
domain (kinase domain) (Fig. 1.1). This similarity in the kinase domains is the key factor defining
the PKC family. Amino-terminal regulatory domains differ between the subclasses. The regulatory
domain is crucial for secondary messenger (molecules that relay signals received at receptors on
the cell surface) binding, binding to the membrane and protein-protein interactions (3).
The regulatory domain of the PKC is comprised of several common sub-regions (Fig. 1.1). The
C1 domain is common in all of the isoforms of PKC and serves as the membrane binding domain.
Both conventional and novel isoforms contain two tandem repetitions of cysteine rich sequences

2

called C1A and C1B. They are essential for the binding of DAG, phorbol esters and membrane
lipids (9–11). However, the C1 domain in aPKCs is incapable of binding to DAG or phorbol esters.
The C2 domain serves as a Ca2+ detector in both cPKCs and nPKCs. Even though C2 is common
to both cPKCs and nPKCs, it serves as a Ca2+ sensor only in cPKCs. C2-like domains in nPKCs
lack essential amino acid residues that facilitate Ca2+ binding (12,13). Atypical PKCs do not have
a C2 domain but they have an additional region called Phox and Bem1 domain (PB1), which is
very important in protein-protein interaction during aPKC activation process (14).
The pseudosubstrate region, which is common in all three main subclasses of PKC, is a small
sequence of amino acids that mimics a substrate and binds the substrate-binding hollow region in
the kinase domain. This region lacks serine and threonine phospho-acceptor residues.
Psedusubstrate binding is a critical phenomenon that keeps the enzyme in its inactive stage (13).
cPKC activation progresses once Ca2+ and DAG are present in optimum concentrations. Calcium
ions bind into C2 and DAG binds into the C1 domain, respectively, which recruit cPKC to the cell
membrane. Interaction of PKC with the membrane leads to release of the pseudosubstrate from the
catalytic site and activation of the enzyme. Yet, PKC must first be properly folded prior to these
allosteric interactions that are necessary for the catalytic action. PKC maturation process starts
with the phosphorylation event on the activation loop with of the catalytic region.
Catalytic domains among kinases are highly conserved. Protein kinase Bs (PKBs) and PKCs
demonstrate approximately 40% amino acid sequence similarity within the kinase domains. This
similarity increases to approximately 70% across PKCs and even higher when comparing within
classes. Selbie et al. reported that two aPKC isoforms, ζ and ι, share ~84% identical kinase domains
(15). Kinase structure is a bilobal structure with a β sheet comprising the N-terminal lobe and an
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α-helix constituting the C-terminal lobe. Both Adenosine-5'-triphosphate (ATP) and substrate
binding sites are located in the cleft formed by these two lobes. The ATP binding C3 motif and
substrate binding C4 motif sequences are highly conserved in the kinase core among other kinases
(3,15).

Figure 1.1 Structural differences of PKCs between subclasses. Highly conserved C-terminal
catalytic domain contains three sites are essential for the activation. Activation loop, turn motif
and hydrophobic motif. These sites get phosphorylated and participate for the activation except
the hydrophobic motif of aPKCs which contains a glutamic acid (E) residue. The PKCs differ in
the regulatory domains. Conventional PKCs have C2 (Ca2+ binding domain), C1A (DAG binding)
domain, C1B (PS binding) domain. The novel PKCs have C domain similar to conventional PKCs.
The C2 domain is altered and incompetent of binding to Ca2+, thus called “novel C2” or “C2-like”.
The C1 domain of atypical PKCs bind to only PS. Instead of the C2 domain, they have the PB1
domain that is involved in protein-protein interaction. All PKCs have a pseudosubstrate domain
within the N-terminal domain.

4

1.4 PKC regulation
Several critical post-translational and mechanistic steps are required for the complete maturation
of the PKC. Among these, phosphorylation of the PKC catalytic region is essential. cPKCs and
nPKCs have three phosphorylation sites, termed: the activation loop, the turn motif, and the
hydrophobic motif. These phosphorylation events are essential for the activity of the enzyme, and
3-phosphoinositide-dependent protein kinase-1 (PDK1) is the upstream kinase responsible for
initiating the process by phosphorylation of the activation loop (16).
The processing of cPKC and nPKC to their mature and functional form involve three sequential
phosphorylations (17,18). Phosphorylation at the activation loop by PDK-1 promptly recruits a
conformational change that involves autophosphorylation at the turn motif, which is very
important in the maturation of PKCs. It protects the catalytically activated form of PKC from
thermal degradation and from proteolysis (19,20). Autophosphorylation at hydrophobic motif
takes place immediately after the autophosphorylation in turn motif (21,22). The aPKCs are
phosphorylated only at the activation loop and the turn motif (Fig. 1.1). Phosphorylation of the
hydrophobic motif is not required as a result of the presence of a glutamic acid in place of a serine,
which provides a negative charge and acts similar in manner to a phosphorylated serine residue of
cPKCs and nPKCs (3).
The pseudosubstrate remains at its substrate binding pocket even after phosphorylation. Upon
extracellular stimulation, phospholipase C converts phosphatidylinositol to phosphatidylinositol 3
kinase (PI3K) and DAG. This lead to release of Ca2+ ions from internal stores. Ca2+ ions binds to
the C2 domain of cPKC inducing partial interaction with anionic phospholipids at the membrane,
which causes conformational changes in the protein, releasing the pseudosubstrate (23). On the
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other hand, nPKCs do not have the Ca2+ binding C2 domain and therefore depend on the C1 domain
to interact with the membrane.
Anchoring proteins play a critical role in the distribution and localization of PKCs which is also
important for the optimum biological functioning. Receptors for activated C- kinases (RACKs)
target PKCs to specific cellular localization by binding with them (24). Substrates that interact
with C-kinase (STICKs), are a group of proteins that bind with immature PKCs to bring them close
to processing cofactors and release them once phosphorylation events take place (25).
The open conformation of activated PKCs is sensitive to proteases like Calpain and
dephosphorylation by phosphatases such as protein phosphatase 2 (PP2A) (26). PKCs are removed
by degradation via ubiquitin-proteosome pathway in their regulation cycles (27,28). Therefore,
protection and proper localization are essential for activated PKCs to perform their function.

1.5 Atypical PKC activation
As already discussed, aPKCs do not depend on DAG and Ca2+ for the activation. Chou et al.
demonstrated that PDK-1 binds with high affinity to the PI3K lipid product phosphatidylinositol3,4,5-trisphosphate (PIP3), phosphorylates and potently activates two other PI3K targets, AKT and
p70S6K. They investigated whether PDK-1 is the kinase that activates PKC-ζ. In-vivo results show
that PI3K is both necessary and sufficient to activate PKC-ζ (29). PDK-1 phosphorylates threonine
410 (T410) in the PKC-ζ activation loop and activates PKC-ζ in-vivo in a PIP3 enhanced manner.
T403 serves as the targeted phosphorylating site for PDK-1 in PKC-ι, which is similar to T410 in
PKC-ζ (29).
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Figure 1.2 Activation process of a conventional PKC. PDK-1 initiates the activation process by
phosphorylating the activation loop at the C-terminal. This stimulates two rapid autophosphorylation events at the turn motif and the hydrophobic motif, respectively. These
phosphorylating events lead the inactive PKC into the cytosol and promote scaffold binding. The
inactive status is maintained by keeping pseudosubstrate (PS) bound to the substrate binding
domain. The subsequent steps in the activation are triggered by signals that promote the lipid
hydrolysis from the membrane and release cofactors such as Ca2+ and DAG. These events promote
the translocation of the PKC to the cell membrane where the co-factors bind to the complementary
regions of the PKC. Ca2+ binds to the C2 domain and DAG binds to C1 domain. The binding of
the co-factors generate the energy required to release the pseudosubstrate form the substrate
binding site and completes the activation. This Figure was adapted from Newton et al. (22)

1.6 PKC superfamily and cancer
PKCs are specific signaling molecules that link multiple cellular processes to cancer. A large
amount of work established PKCs as multifunctional regulators of cell functions such as cell
proliferation, differentiation, survival, migration and invasion (30,31). PKCs have been associated
with a number of diseases such as metabolic disorders, cardiovascular dysfunctions and cancer.
The complexity in PKC signaling and biological functions is largely due to the fact that PKC
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superfamily is a large structurally and functionally diverse group of kinases. In recent years there
have been major advances in the understanding of PKC functions in tumor development,
progression and metastasis. The PKC isozyme expression profile often changes in neoplastic
diseases compared to normal tissues and has therefore been of interest (31).
PKC-α is well known as a regulator of multiple aspects of tumor growth, including proliferation,
survival, differentiation and motility (32). Many reports have demonstrated the oncogenic
properties of PKC-α that linked to enhanced proliferation and anti-apoptotic signals (32–36). As a
result of that PKC-α earned attention as a potential target for cancer therapy. Some literature
reports PKC-α acts as a tumor suppressor. PKC-α is found to be up-regulated in bladder,
endometrial, and breast cancers and down-regulated in colorectal and renal cell carcinomas
(37,38). Hill et al. reported that PKC-α plays a key role in K-RAS-mediated lung tumorigenesis
(39). PKC-α silenced mice demonstrated enhanced K-RAS lung tumorigenesis (39).
The PRKCB gene encodes PKC-βI and PKC-βII, which are splice variants and show a distinctive
involvement in cancer (40). Several reports show the involvement of PKC-β isoforms in the
progression of many cancer types such as glioblastoma, breast, lymphoma, prostate, and colon
cancers (40–44).
PKC-δ is a well-known pro-apoptotic and anti-proliferative PKC isoform (45,46). PKC-δ is widely
used as a death mediator of chemotherapeutic agents and radiotherapy (45–48). PKC-δ
involvement in DNA damage and receptor-mediated cell death has been reported in the literature
(30,48,49).
PKC-ε is found to be upregulated in many cancers mainly through RAS-RAF1 pathway (50–56).
PKC-ε-transformed fibroblasts produced elevated levels of transformed growth factor beta (TGF-
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β) which indicated growth autocrine loops which may account for its oncogenic activity (57,58).
PKC-ε is overexpressed in ~75% of primary tumors from invasive ductal breast cancer patients
(59). PKC-η has also been shown to be up-regulated in some cancers (60,61) but down-regulated
in others (62).

1.7 Atypical PKCs in cancer progression
Regardless of the debates in the literature largely due to the use of non-specific approaches such
as inhibitory peptides and dominant-negative mutants, many studies suggest a tumor suppressor
function of PKC-ζ. In contrast, PKC-ι solidly satisfies the criteria of an oncogenic kinase (62,63).
Variations of the expression of PKC-ζ has been shown in different types of human cancer.
Overexpression of PKC-ζ has been reported in lymphoma, prostate and bladder cancers (63–67).
Interestingly, down-regulation of PKC-ζ has been shown in kidney, renal clear cell carcinoma,
glioblastoma, lung, pancreatic, colon and ovarian cancers (68–78). As an example, PKC-ζ inhibits
growth and promotes apoptosis in colorectal carcinoma demonstrating an inhibitory effect on the
transformed phenotype of colorectal cancer cells. This suggests that down-regulation of PKC-ζ
may contribute to colon tumorigenesis (77). Similarly PKC-ζ demonstrated pro-apoptotic behavior
in ovarian cancer (78). PKC-ζ knock out in-vivo models demonstrated increased RAS induced lung
carcinogenesis, indicating the tumor suppressor features of PKC-ζ in-vivo. In this study, PKC-ζ
downregulates RAS induced interleukin (IL)-6 production in-vivo. Consistent with this finding,
increased production of IL-6 was observed in PKC-ζ knock out cells, which was essential for
cancer cell growth under limited nutrient conditions (73). Futhermore PKC-ζ activity demonstrated
a significant correlation with phosphatase and tensin homolog (PTEN) levels in human prostate
tumors. PKC-ζ knock out in mice showed PTEN deficiency which correlated with elevated
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invasiveness (73). Loss of PKC-ζ promotes human cancer cells reprograming of their metabolism
in response to glucose deprivation by augmenting the utilization of glutamine through the serine
biosynthetic pathway (79).
However, in contrast to PKC-ζ activity described above, some reports show pro-survival antiapoptotic behaviors of PKC-ζ in certain systems (80–85). Win et al. reported that PKC-ζ induced
transformed non-malignant and malignant prostate cell survival by phosphorylating IKKαβ
thereby promoting NF-κB activation (80). Filomenko et al. reported that PKC-ζ is activated and
provides protection in tumor cells which are exposed to a cytotoxic agent (81). Bezombes et al.
showed that PKC-ζ overexpression resulted in delayed apoptosis and provided a significant
resistance to antileukemic drugs in U937 human leukemia cells (82). Cataldi et al. reported that
PKC-ζ generates a survival response with accelerated nuclear translocation to provide a radio
resistance in friend erythroleukemia cells in radiation treatments (83). Xin et al. showed that PKCζ abrogates the proapoptotic function of Bax through phosphorylation in both small cell lung
cancer and non-small cell lung cancer cells (84).
Accumulating evidence recognizes that PKC-ι is an oncogenic kinase and that it contributes to the
transformed phenotype (86,87). Overexpression of PKC-ι is detected in several human tumors,
including lung, colon, breast, pancreas, prostate, melanoma and ovarian cancer (87). The PRKCI
gene is reported to be amplified in some human cancers, even if PKC-ι overexpression does not
necessarily associate with gene amplification (86–92).
PKC-ι is upregulated in non-small cell lung cancer (NSCLC) cells, which is required for the
transformed phenotype of NSCLC cells harboring oncogenic K-RAS mutation (93–96). NSCLC
cell lines highly depend on PKC-ι even without RAS mutation and these situations typically
demonstrated PRKCI gene amplification (96). Justilien et al. reported Rho-GEF Ect2 as an element
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of the PKC-ι/Par6 complex, which is required for transformed growth (97). The epithelial celltransforming Sequence 2 (ECT2) gene was reported to be amplified with PRKCI, which indicates
a coordinated mechanism for tumorigenesis. The anti-rheumatic agent aurothiomalate (ATM) was
used as an inhibitor, which targets PKC-ι/Par6 interaction. ATM was tested against several PKCι overexpressing cell lines. ATM was effective against K-RAS mediated expansion of
bronchoalveolar stem cells and lung tumor growth in-vivo (94,98). ATM was the first drug that
targeted PKC-ι and was considered as a novel therapeutic by Stallings-Mann et al. in 2006. Half
maximal inhibitory concentration (IC50) of ATM ranged from 0.3-100 μM and indicated that some
cell lines are insensitive (i.e. H460 and A549 lung cancer cells). Importantly, ATM has the
potential risk of developing gold toxicity even with low levels of the inhibitor, which is a common
problem with gold therapy in rheumatoid arthritis. Acevedo-Duncan et al. introduced ICA-1 as a
PKC-ι specific inhibitor in 2009 and its nucleotide analog was tested and reported by Pillai et al.
in neuroblastoma cells in 2011, which demonstrated an IC50 of 0.1 μM, which was 1000 times less
than the ATM IC50 in BE(2)-C neuroblastoma cells (99). The study also shows that PKC-ι is
critical for the survival and progression of neuroblastoma cells in-vitro. Desai et al. reported that
PKC-ι is essential for the cell cycle progression of glioblastoma cells through PI3K/PKC-ι pathway
(100). Acevedo-Duncan et al. demonstrated that PKC-ι along with PKC-βII phosphorylate cyclin
dependent kinase activating kinase during the cell cycle in human glioma progression (101). Both
in-vitro and in-vivo results demonstrated that PKC-ι was responsible for cell survival and
progression in colon and pancreatic cancers (90,91). PKC-ι plays a critical role for hedgehog
signaling in basal cell carcinomas. Elevated PKC-ι is responsible for upregulation of the
homoeodomain (GLI1) transcription factor in basal carcinoma cell lines (102). PKC-ι plays a vital
role in antagonistic regulation with RhoB in glioblastoma cells to increase cellular invasion (103).
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Win et al. and Ishiguro et al. have discussed the involvement of PKC-ι in the activation of the NFκB pathway by increasing the phosphorylation of IKKαβ (80,104). Involvement of aPKCs in
different types of cancer progression increased the attention to investigate aPKC role in other
cancers as well including melanoma.
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CHAPTER 2
MELANOMA

2.1 Introduction
2.1.1 Epidemiology
Melanoma is a lethal malignancy that has attracted a huge attention since the beginning of the 21st
century. Even though incidences of many tumor types are decreasing, malignant melanoma
incidences are in a rapid rise (105). Although most patients have localized tumors at the diagnosis
point, which can be effectively removed surgically, the majority of patients develop metastases
later (106,107). Increasing numbers of malignant melanoma have created a worldwide socioeconomic problem. A century ago, melanoma cases were very rare, but today it is one of the most
frequent cancers in the Caucasian population (108,109). As of the beginning of 2019, melanoma
is regarded as the fifth most common cancer in the United States (US). According to the
surveillance, epidemiology, and end results (SEER) statistics of the US national cancer institute,
~92,000 new melanoma incidences were reported in the year 2018, which was approximately 5.3%
of all cancers reported (105). According to the SEER data, new malignant melanoma cases
increased by approximately 300% since 1975. In 1973, the US melanoma incidence rate was 6.8
per 100,000 and in 2018, the rate was reported as 23.75 per 100,000, in which the rate for men was
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29.8 per 100,000 and 17.7 per 10,000 for women. This suggests that men are more susceptible
than women for the disease.
Researchers believe that a major cause for this difference may lie in men’s skin which differs from
women’s skin. Men have thicker skin with less fat beneath. A man’s skin also contains more
collagen and elastin, fibers that give the skin firmness and keep it tight. These differences make
men’s skin more likely to be damaged by the sun’s ultraviolet (UV) rays (108). Mackie et al. shows
that Australia has the highest recorded incidence of melanoma worldwide (110). The average of
new melanoma incidence is 55.8 per 100,000 per annum for males and 41.1 per 100,000 per annum
for females from 1983 to 2002. New Zealand comes second in the world after Australia, and
Switzerland, Norway, Sweden and Denmark report the highest number of cases in European
countries, respectively (110). Africans, Middle-eastern and Asians have shown much lower
numbers, which is probably due to better protection against UV rays which is typical of highly
pigmented skin (106). The incidence rate of melanoma for the white population has an
approximately 10-fold greater risk of developing cutaneous melanoma than black, Asian or
Hispanic populations. At the same time, both white and African American populations share an
equal risk of developing malignant melanoma in plantar locations (bottom of the foot).
Interestingly, non-cutaneous melanomas such as mucosal melanoma are more common in nonwhite populations (106,110,111).
According to the SEER data for 2018, the median age at diagnosis of melanoma is 64 in the US.
Markovic et al. reported that men are approximately 50% more likely to develop melanoma than
women. However, this difference increased to approximately 300% when the average age reaches
75 years where the new incidence rate for men is 145.6 per 100,000 against 47.3 per 100,000 for
women (106,112). Interestingly, data also shows a difference in the distribution of the disease
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between men and women. The most frequent site of occurrence for men is the back while arms
and legs are the most common sites for women (113).
Melanoma is caused by many factors, usually a combination of genetic susceptibility and
environmental exposure. The most important environmental risk factor for developing malignant
melanoma is the exposure to genotoxic UV rays (106,108). Elwood et al. reported that prolonged
sun exposure appears to be a major risk for melanoma (109). Artificial UV exposure also plays a
role in the development of melanoma. Psoralen–UVA radiation photochemotherapy used to treat
psoriasis leads to an increased risk of melanoma (114). Presence of melanocytic nevi, family
history and genetic susceptibility are the most important host risk factors. Melanocytic nevi are
benign accumulations of melanocytes or nevus cells that can be congenital or acquired.
Approximately 25% of melanoma cases can be related to a pre-existing nevus (115). Moreover,
the higher the number of nevus and the higher the size increases the risk of melanoma (116,117).
Atypical nevi are frequently associated with an increased risk of melanoma.
Family history is another strong risk factor for melanoma, indicative of possible heritable genetic
causes. According to Tsao et al., families with inherited melanoma demonstrated a clear pattern
of autosomal-dominant inheritance with numerous family members affected, in which cyclindependent kinase inhibitor 2A (CDKN2A) was found as the most common genetic abnormality
(118,119). Patients with an underlying genetic susceptibility to develop melanoma usually
demonstrate occurrence at a very young age (<40 years). Multiple primary tumors or a history of
precursor lesions (e.g. dysplastic nevi) form tumors that are superficially invasive and with a better
prognosis (118). Certain phenotypic characteristics such as fair skin, red hair, freckles, sun
sensitivity and an inability to tan, show greater risk of developing melanoma (119).
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2.1.2 Melanoma stages
There are four main types of skin melanoma. The most common type is superficial spreading
melanoma. It is more commonly found on the back, arms, legs and chest. Superficial spreading
melanoma grows slower at the beginning and speeds up eventually. The second most common
type is nodular melanoma, which grows faster than other types. Color typically changes from red
to black over the time when tumors grow. It is commonly found on the neck, chest, back and head.
The third type is called lentigo maligna melanoma, which is less common compared to the previous
two. It is usually found in older people in areas such as the face and neck that have had a lot of sun
exposure over a long time. It develops from a slow-growing precancerous condition called a
lentigo maligna or Hutchinson’s freckle. This looks like a stain on the skin. They are usually slowgrowing and less dangerous than the other types of melanoma. The last of the four, and the rarest
type, is called acral lentiginous melanoma. It is usually found on the palms of the hands, soles of
the feet, or under fingernails or toenails. It is more common in people with black or brown skin.
Acral lentiginous melanoma is a dangerous melanoma form that grows at a faster rate. Apart from
these four types, another rare type of melanoma is called desmoplastic melanoma. Rarely,
melanoma can start in parts of the body other than the skin, such as in the eye, which is called
ocular melanoma. Sometimes it can start in the tissues that line areas inside the body, such as the
anus or rectum, nose, mouth, lungs and other areas.
The stage of a melanoma describes how deeply it has grown into the skin, and whether it has spread
away from the primary tumor. Clark scale and Breslow scale are most frequently used systems to
classify melanoma. These scales are different from each other and doctors often use both to
interpret the disease with the stage numbering because Clark and Breslow scales only look at the
depth of melanoma cells in the skin.
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The Clark scale is a way of measuring how deeply the melanoma has grown into the skin and
which levels of the skin are affected. The Clark scale has 5 levels: level 1 is also called melanoma
in situ where melanoma cells are present only in the epidermis (outer layer of the skin). Level 2
means there are melanoma cells in the papillary dermis, which is the layer directly under the
epidermis. In level 3, melanoma cells distribute throughout the papillary dermis and start to spread
into the next layer down (the reticular dermis). Level 4 means the melanoma has spread into the
reticular or deep dermis. Level 5 means the melanoma has grown into the layer of fat under the
skin (subcutaneous fat). For the Breslow scale, the pathologist measures the thickness of the
melanoma tumor. It measures in millimeters (mm) how far melanoma cells have reached down
through the skin from the surface.
In general, melanoma can be categorized into 5 stages (116,120). In stage 0 melanoma, the tumor
is confined to the upper layers of the skin and have not grown deeper. Stage I melanoma is defined
as a tumor that is up to 2mm thick. A Stage I melanoma may or may not have ulceration, but there
is no evidence the cancer has spread to lymph nodes or metastasized. Stage II melanoma is defined
by tumor thickness with ulceration. Still there is no evidence the cancer has spread to the lymph
nodes or distant sites. Stage III melanoma is defined by the level of lymph node involvement and
ulceration. In Stage III melanoma, the depth of the melanoma no longer matters. There is no
evidence the cancer has spread to distant sites. Stage IV melanoma occurs when the cancer spreads
beyond the original site and regional lymph nodes to more distant areas of the body. The most
common sites of metastasis are lungs, abdominal organs, brain, bones and soft tissues such as other
parts of the skin and distant lymph nodes beyond the primary tumor region (116,120).
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2.1.3 Melanoma diagnosis and currently available treatments
Early detection is the most important factor for lowering the malignant melanoma mortality.
Timely detection and proper treatment is critical for higher survival rate. Compared to other lethal
cancers malignant melanoma has the assistance of the cutaneous location, which allows its early
detection through non-invasive approaches and provides a better chance to apply non-invasive
treatments. Pathological examination plays one of the most important steps in the diagnosis. Skin
self-examination is a simple, convenient method of screening for melanoma and precancerous
lesions (116,120). The “ABCDE” criteria was developed in 1985 for the identification of
melanoma. ABCDE stands for “asymmetric” mole, “border” (irregular border), “color” (changes
over the time), “diameter” (>6 mm) and “evolving”. This criteria is applied for differentiating
common moles. Glasgow 7-point checklist is another clinical tool used to identify melanoma,
which includes three major factors which are change in “size”, “shape” and “color”. Additionally,
it considers four minor factors which are “sensory change”, “diameter change”, “inflammation”
and “bleeding” (106). Dermoscopy is also a non-invasive diagnostic method for in-vivo
observation of the skin; this device uses optic magnification to provide a better visualization of
morphological structures that are not visible to the naked eye.
Atypical pigment network changes, appearance of irregular dots/globules, irregular streaks,
irregular pigmentation are used to spot malignant lesions. Regression structures are also a
characteristic of malignant lesions. During the process of regression, fibrosis and melanosis are
usually found together and, thus, the regression structures appear as white scar-like areas, blue
areas or a combination of both (121).
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Total-body photographic images and short-term surveillance can also be used to detect minimal
changes in the early stages of melanoma tumor development. This approach gives viability to
assess dynamic evolution of the melanocytic nevi over time (121).
For stage IV melanoma, the National Comprehensive Cancer Network recommended first line
agents are dabrafenib, ipilumumab, vemurafenib, and high-dose IL-2. Most of these drugs target
proto-oncogene B-Raf (BRAF) mutation (V600E), which occurs in ~60% melanoma cases, yet
melanoma has a poor prognosis and tumors acquire resistance to BRAF mutation inhibition (122).
Currently available and United States Food and Drug Administration (FDA) has approved
combination therapies for advanced melanoma include dabrafenib + trametinib and vemurafenib
+ cobimetinib. These may improve survival, but they also pose adverse toxic effects (123,124).
The FDA approved only decarbazine as a chemotherapeutic drug for melanoma which has only 712% response rate (124). Isolated limb perfusion/infusion, interferon-α therapy, topical imiquimod
therapy, cryotherapy, radiation therapy, and intratumoral interleukin-2 injections are also available
as new emerging treatment methods. Another new class of treatment include anti-programmed
death-ligand 1 agents, anti-programmed cell death 1 receptor agents such as nivolumab and
pembrolizumab, and oncolytic vaccines. Available treatments for selected sites include adoptive
T-cell therapies and dendritic cell vaccines. Patients with Stage IV melanoma continue to
demonstrate a poor prognosis, with a mean survival of only 8–10 months (124).
Surgery is an effective option for early stage melanoma, since patients are quickly rendered
“disease-free” as a result of removal of localized tumors. In contrast, systemically administered
therapies require prolonged treatment courses to achieve relatively inferior local response rates.
But surgery alone cannot identify and address microscopic metastases, and once the disease
reaches later stages, the effectiveness of surgeries decreases (125).
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More recently, isolated limb perfusion (ILP) has developed as an effective limb salvaging therapy
for regional cutaneous and subcutaneous metastases. In ILP, high chemotherapy doses are
delivered locally to the patient under an extracorporeal circuit that isolates the affected limb, which
avoids systemic toxicity. The rationale of ILP is that there is high localized doses of cytotoxic
agents applications with minimal systemic adverse events. In cryotherapy, liquid nitrogen is used
as a non-invasive targeted treatment for limited cutaneous metastatic melanoma (126).
Cryotherapy results in tumor antigen release through local trauma to the area and thereby providing
potential to elicit a systemic anti-melanoma immune response. However, outcomes of this method
was not as efficient as expected earlier (127). Radiation therapy (RT) is commonly used as an
additional therapy or as palliative therapy, particularly for patients with brain metastases and is
carried out as sterotactic gamma knife radiosurgery (128). In the setting of inoperable disease, RT
is a rational option for palliation.
In the late 1990s, the FDA approved high-dose intravenous IL-2 as an immunotherapy for
metastatic melanoma. IL-2 is a glycoprotein secreted by T helper cells. It stimulates T-cell
proliferation and the development of lymphokine-activated killer (LAK) cells, which have the
ability to directly lyse tumor cells (129). Intravenous delivery of IL-2 provides an overall response
rate only 16% in patients with metastatic melanoma (130). Due to IL-2-induced vascular leak
syndrome and other associated toxicities, intravenous IL-2 therapy is rarely used nowadays.
Intralesional approach for IL-2 administration was tested to reduce systemic toxicity and increase
local therapeutic effects for treatment of melanoma metastases.
Bacillus Calmette-Guérin (BCG) is an attenuated live bovine tuberculosis bacillus that is used as
a vaccination for human tuberculosis. BCG is used to treat a variety of different malignancies.
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BCG treatments for melanoma showed poor efficacy and increased the risk of death due to
anaphylactic shock and development of infectious granulomas at sites of injection (125,131).
Interferon therapy is also applied against metastatic melanoma. IFN-α is a type 1 interferon
endogenously produced by macrophages, T cells, and natural killer cells that have shown antitumor properties. However, IFN-α for the treatment of metastatic melanoma survival outcomes
have been largely inconsistent between different trials. Both autologous and allogenic cancer
vaccination strategies have been used in metastatic melanoma but response rates were not
consistent (132,133).
The programmed cell death 1 receptor (PD-1), expressed by T cells, which has two primary
ligands; PD-L1, found on cancer cells and tumor-infiltrative macrophages; and PD-L2, found on
antigen-presenting cells. PD-1 acts as a negative regulator of T cells. As with anti-CTLA-4 (cluster
of differentiation 152) therapy, antibodies against both PD-L1 and PD-1 have been developed to
inhibit this down-regulatory pathway, allowing for unopposed T-cell activation (133,134). The
purpose of this is to activate tumor-specific T cells and “bystander” T cells that may also contribute
to the anti-cancer response. Recent phase I trials of nivolumab (anti-PD-1) in combination with
ipilimumab (anti-CTLA4) and BMS936559 (anti-PD-L1) showed promising results in patients
with advanced melanoma (134).

2.1.4 Atypical PKC expression in melanoma
PKC expression in melanocytic lineage cells has enticed a great deal of consideration because
phorbol esters needed for PKC activation are also essential components for the in-vitro growth of
normal human melanocytes. In addition, phorbol esters have been reported to promote the
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development of skin tumors (135–137). Other evidence associated with PKC involvement in
melanoma is that bryostatins are currently being evaluated in the treatment of human melanoma
which can also increase PKC activity (138–141). Therefore, to obtain a proper understanding of
the role of various PKC isoforms in the process of transformation of human melanocytes, it is
essential to know the distribution of PKC isoforms and ultimately their levels of activation in
melanoma samples. Various research groups have shown that changes in PKC isoform expression
are associated with alterations in growth and differentiation of specific human melanocyte
functions. Selzer et al. conducted a full characterization of the distribution pattern and expression
differences between normal and malignant melanocyte samples. They investigated the presence of
11 PKC isozymes in eight metastatic melanoma samples, 3 normal melanocyte cell lines and 3
spontaneously transformed melanocytes and several other melanoma tumor samples. Both PKC-ι
and PKC-ζ showed a distinct difference in their expression when moving from the normal status
to malignant through transformation. Elevated levels of PKC-ζ and PKC-ι were found in all
transformed melanocytes and melanoma metastases samples. PKC-ζ was detected in normal
melanocytes in low levels. But PKC-ι were absent in normal melanocytes (135). These results
suggest that transformation of normal to malignancy of melanocyte tumors demonstrate a positive
relationship with the expression of aPKCs thereby indicates that melanoma progression depends
on aPKCs.

2.2 Results
We tested the aPKC expression in two normal melanocyte cell lines (PCS-200-013 and MEL-FNEO) against two melanoma cell lines (SK-MEL-2 and MeWo) at 50% and 100% confluency.
Figure 2.1 demonstrates a comparison of the expression of PKC-ι and PKC-ζ in normal
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melanocytes (PCS-200-013 and MEL-F-NEO cell lines) against SK-MEL-2 and MeWo malignant
melanoma cell lines. As shown in Figure 2.1, PKC-ι was not detected in normal melanocyte cell
lines compared to the over-expression observed in SK-MEL-2 and MeWo malignant melanoma
cell lines. Moreover, PKC-ζ expression was very low in both normal melanocyte cell lines
compared to the amplified expression in melanoma cells. These results agreed with the expression
patterns demonstrated by different cell lines and patient samples described in Selzer et al. (135).

Figure 2.1: aPKC expression comparison between normal melanocytes (PCS-200-013 and MELF-NEO) and melanoma cell lines (SK-MEL-2 and MeWo). The expression of PKC-ι and PKC-ζ
was reported at approximately 50% and 100% confluency for normal melanocytes against
metastatic melanoma cells. Western blots were conducted with 50 μg of total proteins loaded in
each lane. Experiments (N = 3) were performed.

2.3 Summary
When taken together, these results indicate a strong relationship between aPKCs and melanoma
progression. The exact roles of these aPKCs in melanoma progression were systematically studied
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and findings are reported in this dissertation and in the form of full published research articles
(142–145).
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CHAPTER 3
NOVEL ATYPICAL PKC SPECIFIC INHIBITORS

3.1 Introduction (ACPD, DNDA, ICA-1S, ICA-1T and ζ-Stat)
We have investigated the effects of five novel aPKC specific inhibitors on various cellular aspects
of melanoma such as cellular growth, differentiation, survival, migration and invasion. Figures
3.1-3.5 show 2-acetyl-1,3-cyclopentanedione (ACPD) (Fig. 3.1), 3,4-diaminonaphthalene-2,7disulfonic

acid

(DNDA)

(Fig.

3.2),

[4-(5-amino-4-carbamoylimidazol-1-yl)-2,3-

dihydroxycyclopentyl] methyl dihydrogen phosphate (ICA-1T) (Fig. 3.3) along with its nucleoside
analog

5-amino-1-((1R,2S,3S,4R)-2,3-dihydroxy-4-methylcyclopentyl)-1H-imidazole-4-

carboxamide (ICA-1S) (Fig. 3.4) and 8-hydroxy-1,3,6-naphthalenetrisulfonic acid (ζ-Stat) (Fig.
3.5), which were virtually screened and experimentally validated for the specificities of PKC-ι and
PKC-ζ. All these five inhibitors were identified and characterized by Acevedo-Duncan et al. at the
University of South Florida (99,142,143).
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Figures 3.1-3.5: Structures of the aPKC specific inhibitors (ACPD, DNDA, ζ-Stat, ICA-1S and
ICA-1T). Chemical structures of ACPD (3.1) and DNDA (3.2) are specific to both PKC-ι and
PKC-ζ, ICA-1T (3.3) and ICA-1S (3.4) are specific to PKC-ι while ζ-Stat (3.5) is specific to PKCζ. Molecular weights of ACPD (140.14 g/mol), DNDA (318.32 g/mol), ζ-Stat (MW = 384.34
g/mol), ICA-1S (MW = 256.26 g/mol) and ICA-1T (MW = 336.24 g/mol), respectively.

Aurothiomalate (ATM) was first identified as a potent PKC-ι inhibitor, targeting the interaction
between Phox and Bem1 (PB1) domain of PKC-ι and partitioning defective 6 (Par6) by StallingsMann et al. in 2006 (146). Half maximal inhibitory concentration (IC50) of ATM ranged from 0.3100 μM to the tested cell lines which indicated that some cell lines are insensitive (i.e. H460 and
A549 lung cancer cells) to ATM (98). In addition, ATM has the potential risk of developing gold
toxicity even with low concentrations, which is common in gold therapy in rheumatoid arthritis
(147). The discovery of ICA-1T analog was patented in 2007 and its effects on neuroblastoma was
reported by Pillai et al. as a novel potential inhibitor for PKC-ι in 2011. ICA-1T demonstrated IC50
as 0.1 μM which was 1000 times less than ATM IC50 on BE(2)-C neuroblastoma cells (99). When
ICA-1T was first presented, PKC-ι crystal structure was not available, therefore a PKC homology
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model was used for molecular docking simulations. Pillai et al. reported that ICA-1T is more
potent compared to FDA-approved ATM (99). The inhibitory mechanism of ICA-1T was reported
as competitive therefore rate of the reaction will depend on inhibitor and substrate concentrations.
This suggests that the mechanism of ICA-1T may not involve adenosine triphosphate (ATP)
competitive binding (99).
Sajan et al. reported the specificity of ACPD as it inhibits both PKC-ι and PKC-ζ without affecting
other PKC isoforms in a study which investigated the effects of PKC-ζ in glucose metabolism
(148). Even though the molecular simulations and specificity predictions were not reported, Sajan
et al. reported that ACPD does not interact with other kinases such as adenosine monophosphateactivated protein kinase (AMPK), RAC-beta serine/threonine-protein kinase (Akt2), fibroblast
growth factor receptors (FGFR)1/2/3/4, mammalian target of rapamycin (mTOR), glycogen
synthase kinase 3 beta (GSK3β), Interleukin-1 receptor associated kinase (IRAK), janus kinase
(JAK1/2), mitogen-activated protein kinase kinase 1 (MEK1), mitogen-activated protein kinase
3/6 (ERK1/2), c-Jun N-terminal kinases (JNK1/2), protein kinase A (PKA), proto-oncogene
tyrosine-protein kinase Src (Src), Rho associated coiled-coil containing protein kinase 2 (ROCK2)
and phosphoinositide 3-kinases (PI3K) (149,150).

3.2 Results
3.2.1 Molecular docking predictions and binding affinities
ACPD and DNDA were screened by positioning them in the structural pockets of PKC-ι and PKCζ homology models and then scored based on polar and non-polar interaction predictions. ACPD
interacted with amino acid residues Gln 469, Ile 470, Lys 485 and Leu 488 of the PKC-ι
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homologous structure (Fig. 3.6) and Arg 265, Pro 267, Asp 269 and Lys 290 of the PKC-ζ
homologous structure (Fig. 3.7). DNDA demonstrated interactions with Asp 339, Asp 382, Leu
385 and Thr 395 of PKC-ι (Fig. 3.8) and Asp 337, Asp 380, Leu 383 and Thr 393 of PKC-ζ (Fig.
3.9). Reasonable docking scores were acquired (approximately -7 kcal/mol) for both ACPD and
DNDA separately for PKC-ι and PKC-ζ homologous structures. Molecular docking predictions
suggest that both ACPD and DNDA interact with both PKC-ι and PKC-ζ in a fairly similar manner.
By the time molecular docking experiments of ICA-1T, ICA-1S, and ζ-Stat were performed for
the PKC-ι, the complete crystal structure of PKC-ι was available. We identified an allosteric
binding pocket located within the C-lobe of the kinase domain (Figures 3.10 and 3.11) which is
primarily composed of residues conserved between PKC-ι and PKC-ζ. These data validated the
identification of the druggable pocket as reported earlier by Pillai et al. using a PKC-ι homologous
model with several other biochemical assays (99). In order to determine whether ATP influences
the inhibitor binding, we compared molecular docking scores using ATP bound and unbound
forms of PKC-ι for the affinities of inhibitors. These new molecular simulations with the solved
PKC-ι structure suggested that the ICA-1S and ICA-1T have the potential to interact with PKC-ι
in the presence and absence of ATP with moderate-high affinities. ICA-1T and ICA-1S showed
binding scores of -7.8 and -7.3 kJ/mol in the absence of ATP for PKC-ι and the scores did not
change significantly as a result of the presence of ATP as of -7.6 and -6.7, respectively.
Interestingly, ζ-Stat also demonstrated a higher score for the used structure since the identified
pocket has a conserved amino acid sequence between PKC-ι and PKC-ζ structures. Therefore,
experimental analysis for the inhibitor specificities were essential to provide a solid support for
these molecular docking predictions. Consequently, we conducted kinase activity assays for
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aPKCs in the presence of these compounds using myelin basic protein (MBP), a known PKC
substrate (151).

Figures 3.6-3.9. Molecular Docking of ACPD and DNDA with aPKCs. ACPD interacts with
amino acid residues of 469-488 of the catalytic domain of PKC-ι (3.6) and amino acid residues of
265-290 of the catalytic domain of PKC-ζ (3.7). DNDA interacts with amino acid residues of 339395 of the catalytic domain of PKC-ι (3.8) and amino acid residues of 337-393 of the catalytic
domain of PKC-ζ (3.9).
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Figures 3.10-3.11: Molecular docking of ICA-1T, ICA-1S and ζ-Stat with PKC-ι. Fig. 3.10 shows
the molecular surface of PKC-ι bound to ATP (3A8W) with docked ICA-1T. The molecular
surface of residues that differ between PKC-ι and PKC-ζ are colored based on sequence similarity
(using the Blosum62 scoring matrix). Blosum62 similarity values are: blue, 40–50, cyan, 50–60,
green, 60–70, yellow, 70–90, orange and 90–100, red. Residues that are identical between PKC-ι
and PKC-ζ are colored red. ATP is depicted as sticks with yellow for carbon, red for oxygen, blue
for nitrogen. ICA-1T is depicted as sticks colored by element with white, red, and blue representing
carbon, oxygen, and nitrogen respectively. Fig. 3.11 shows 3 enlarged pictures of lowest energy
docking conformations of ICA-1T, ICA-1S, and ζ-Stat docked in the identified allosteric docking
site, respectively.

3.2.2 Kinase activity assays
Experimental determination of specificities of these inhibitors was essential since PKC-ι and PKCζ has ~84% similarity among kinase domains (15). We conducted an in-vitro kinase activity assay
for all five inhibitors to confirm virtual screening data. Kinase activities of ACPD, DNDA, ICA-
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1T, ICA-1S and ζ-Stat (Figs. 3.12 and 3.13) were determined for a series of concentrations using
recombinant active PKC-ι or PKC-ζ in the presence of MBP. Both ACPD and DNDA
demonstrated significant inhibitions for both PKC-ι and PKC-ζ under all tested concentrations.
Inhibition reached close to the maximum values approximately at 2.5 μM and did not change
significantly thereafter. Nevertheless, the highest inhibitions were recorded at their 10 μM
solutions; ACPD inhibited PKC-ι by 44% (P≤0.05) and PKC-ζ by 41% (P≤0.05) while DNDA
inhibited PKC-ι by 38% (P≤0.05) and PKC-ζ by 29% (P≤0.05).
The specificity of ICA-1T was previously reported as inhibiting only PKC-ι without affecting other
PKC isoforms (99). We tested the nucleoside analog of ICA-1T (ICA-1S) for the first time, which
also shows a significant specificity towards the same allosteric site of PKC-ι. Additionally, the
kinase activity shows that ζ-Stat is specific to PKC-ζ only, which agrees with the molecular
docking predictions even though it used a homology model for PKC-ζ. Both ICA-1S and ICA-1T
showed a significant inhibition of PKC-ι ˃60% (P≤0.05) at approximately 5 μM levels but
resulting in only ~10% inhibition of PKC-ζ at 20 μM. On the other hand, ζ-Stat showed only 13%
inhibition of PKC-ι at 20 μM, but 51% (P≤0.05) inhibition of PKC-ζ at 5 μM. This confirms the
specificities we found for ICA-1T, ICA-1S and ζ-Stat through molecular docking.
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Figures 3.12-3.13: Effects of ACPD, DNDA, ICA-1T, ICA-1S and ζ-Stat on PKC-ι and PKC-ζ
kinase activity. Fig. 3.12 summarizes the effects of ACPD and DNDA while Figure 3.13
summarizes the effects of ICA-1T, ICA-1S and ζ-Stat on recombinant active PKC-ζ or PKC-ι. The
recombinant proteins were incubated with myelin basic protein (MBP) in the presence or absence
of inhibitors (0.1- 10/20 µM) and percentage kinase activity was plotted against inhibitor
concentration. Experiments (N=3) were performed for each experiment and mean ± SD are plotted.

3.2.3 Dose curves of ACPD, DNDA, ICA-1S, ICA-1T and ζ-Stat on normal melanocyte cell
lines and melanoma cell lines
We first determined the dose curves for ACPD and DNDA since they target both aPKC isoforms.
The effects of ACPD and DNDA on cell proliferation of normal and malignant cell lines over a
wide range of concentration were tested. Both ACPD and DNDA did not show a significant
inhibition for MEL-F-NEO normal melanocyte cells (Fig. 3.14), but significantly decreased cell
proliferation of SK-MEL-2 and MeWo upon increasing the concentrations (Fig. 3.15, 3.16, 3.17
and 3.18). ACPD decreased proliferation by 48% at 2.5 µM (P≤0.01) (Fig. 3.15) and DNDA
decreased cell proliferation by 52% at 2.5 µM (P≤0.01) (Fig. 3.16) in the SK-MEL-2 cell line.
ACPD decreased proliferation by 54% at 2.5 µM (P≤0.01) (Fig. 3.17) and DNDA decreased
proliferation by 46% for 2.5 µM (P≤0.01) (Fig. 3.18) in the MeWo cell line. These results suggest
that both aPKC specific ACPD and DNDA can effectively decrease melanoma cell proliferation
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without effecting normal melanocytes. Based on these results the IC50 values of ACPD and DNDA
for both drugs were found to be approximately 2.5 µM, the concentration used in later experiments.
ICA-1T showed no significant effect against MEL-F-NEO (Fig. 3.19) up to 5 µM, but had
maximum inhibition of 22% (P≤0.05) at 10 μM. Both ICA-1S and ζ-Stat showed significant
inhibitions of MEL-F-NEO cells beyond 7.5 μM (P≤0.05) as 37.7% (P≤0.05) and 19.3% (P≤0.05)
at 10 μM, respectively. All inhibitors significantly decreased cell proliferation of SK-MEL-2 and
MeWo at much lower concentrations. ICA-1T decreased proliferation by 53.1% for 1 µM (P≤0.01)
in SK-MEL-2 cells (Fig. 3.20), and 56.1% at 1 µM (P≤0.01) in MeWo cells (Fig. 3.21). ICA-1S
decreased proliferation by 46% at 2.5 µM (P≤0.01) in SK-MEL-2 cells (Fig. 3.20) and 50.7% at
2.5 µM (P≤0.01) for MeWo cells (Fig. 3.21). ζ-Stat decreased proliferation by 47.7% at 5 µM
(P≤0.01) in SK-MEL-2 cells (Fig. 3.20) and by 50.6% at 5 µM (P≤0.01) for MeWo cells (Fig.
3.21). These results suggest that ICA-1T, ICA-1S and ζ-Stat can effectively be used to decrease
melanoma cell population at lower concentrations at which they do not significantly effect on
normal melanocytes. IC50 values of ICA-1T, ICA-1S and ζ-Stat were found at approximately 1
µM, 2.5 μM and 5 μM, respectively, for both cell lines. Later, we used these concentrations in
experiments as the testing concentrations.

33

Figures 3.14-3.18. Effects of ACPD and DNDA on cell proliferation of normal melanocytes and
malignant melanoma cells. Results depict the effect of ACPD and DNDA on PCS-200-013 (3.14),
ACPD on SK-MEL-2 (3.15), DNDA on SK-MEL-2 (3.16), ACPD on MeWo (3.17) and DNDA
on MeWo (3.18). Approximately 4 × 104 cells were cultured in T25 flasks and treated with either
equal volume of sterile water (control) or ACPD or DNDA (0.1- 3.5 µM). Additional doses of
sterile water or ACPD or DNDA were supplied every 24 h during a 3 day incubation period.
Subsequently, cells were lifted and counted. Cell count for PCS-200-013 cells were only obtained
for 3 days due to longer doubling time. The two malignant cell lines (SK-MEL-2 and MeWo) were
quantified by counting the viable cells at 24 hour intervals. Experiments (N=3) were performed
for each cell line and mean ± SD are plotted. Statistical significance is indicated by asterisks as
*P< 0.05 and **P < 0.01.
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Figures 3.19-3.21: The effects of ICA-1T, ICA-1S and ζ-stat on cell proliferation and cell viability
for melanoma and normal melanocyte cells. Results depict the effect of inhibitors on MEL-F-NEO
(Fig. 3.19), SK-MEL-2 (Fig. 3.20) and MeWo (Fig. 3.21) cell proliferation based on cell
proliferation assay. Approximately 4 × 104 cells were cultured in T25 flasks and treated with either
equal volume of sterile water (control) or inhibitors (0.1- 10 µM). Additional doses of sterile water
or inhibitors were supplied every 24 h during a 3 day incubation period. Subsequently, cells were
lifted and counted. Experiments (N=3) were performed for each cell line and mean ± SD are
plotted. Statistical significance is indicated by asterisks as *P< 0.05 and **P < 0.01.
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3.2.4 WST-1 assays for cellular toxicity effects of ACPD, DNDA, ICA-1S, ICA-1T and
ζ-Stat
4-[3-(4-Iodophenyl)-2-(4-nitropheny))-2H-5-tetrazolio]-1,3-benzene disulfonate (WST-1) assay
was performed to determine the in-vitro cytotoxicity of the inhibitors. The absorbancy at 450 nm
is directly proportional to the number of viable cells present. Viable cells produce a water-soluble
formazan with WST-1 as a result of their mitochondrial dehydrogenase activity.
aPKC inhibitors ACPD and DNDA did not show a significant effect on normal melanocyte cells
(Fig. 3.22), but DNDA showed relatively high toxicity against both cell lines at its IC50 value (Fig.
3.23 and 3.24).
In terms of PKC-ι specific ICA-1T and ICA-1S along with PKC-ζ specific ζ-Stat, none of the
inhibitors showed significant cytotoxicity against normal melanocytes (Figure 3.25). ICA-1T
showed a significant cytotoxicity towards both melanoma cell lines, followed by ICA-1S. ζ-Stat
did not show significant cytotoxicity any of the cell lines (Fig. 3.26 and 3.27).
These results indicate that all inhibitors appeared cytostatic more than being cytotoxic during the
tested time ranges, thereby retarding melanoma cell growth and proliferation. This could indicate
that melanoma cells undergo a phase where their growth and differentiation stops before their
apoptotic stimulation as a result of aPKC inhibition.
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Figures 3.22-3.27: The effects of aPKC inhibitors (ACPD, DNDA, ICA-1T, ICA-1S and ζ-stat)
on cytotoxicity for melanoma and normal melanocyte cells. Cytotoxicity of aPKC inhibitors was
measured using WST-1 assay and the results indicate as ACPD and DNDA for MEL-F-NEO (Fig.
3.22), SK-MEL-2 (Fig. 3.23) and MeWo (Fig. 3.24) cells. Similarly, cytotoxicity of ICA-1T, ICA1S and ζ-Stat indicates for MEL-F-NEO (Fig. 3.25), SK-MEL-2 (Fig. 3.26) and MeWo (Fig. 3.27)
cells. The absorbance at 450 nm is due to production of water soluble formazan and was measured
as a function of time. The absorbance is directly proportional to the number of cells. Experimental
concentrations in WST-1 assay for ACPD, DNDA, ICA-1T, ICA-1S and ζ-Stat were 2.5 μM, 2.5
μM, 1 μM, 2.5 μM and 5 μM, respectively for all three cell lines. The absorbance at 450 nm against
time is plotted. Experiments (N=3) were performed for each cell line and mean ± SD are plotted.
Statistical significance is indicated by asterisk as *P< 0.05 and **P < 0.01.
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3.3 Summary
The computational screening and kinase activity assay data show that ACPD and DNDA are
specific inhibitors of aPKCs. ACPD showed the same effect as an inhibitor for both PKC-ζ and
PKC-ι in a relative sense. DNDA showed a better action on PKC-ι over PKC-ζ.
Our virtual screening and kinase activity assays confirmed the specificity of ICA-1T and ICA-1S
for PKC-ι and ζ-Stat specificity on PKC-ζ. We also were able to confirm the presence of a
potentially druggable allosteric site in the structure of PKC-ι using a solved crystal structure of
PKC-ι, which was initially predicted by Pillai, et al. using a PKC-ι homology model (99). This
site, within the C-lobe of the kinase domain, is framed by solvent exposed residues of helices ⍺F⍺I and the activation segment. ICA-1T and ICA-1S were predicted to interact with this site with
higher-moderate affinity based on molecular docking. Combinations of drugs targeting the ATP
binding site and allosteric sites would be expected to more effectively inhibit cancer cell growth.
Assessing the cell viability and cytotoxicity of malignant and normal cells for inhibitors were
crucial, considering our ultimate intent was to determine if the inhibitors had potential as
therapeutic drugs. All five inhibitors were non-toxic to normal melanocytes. Overall, all five
inhibitors showed more cytostatic properties on melanoma cells with a mild toxicity provided by
DNDA, ICA-1T and ICA-1S at their IC50 values. The results show that these inhibitors are
effective in arresting malignant melanoma cells in terms of their growth, differentiation and
proliferation before they induce apoptosis. This confirms that malignant melanoma cells are highly
dependent on aPKCs to remain viable, supporting our previous data that both melanoma cell lines
overexpress aPKCs compared to the undetectable PKC-ι and low levels of PKC-ζ in normal
melanocytes (Fig. 2.1).
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CHAPTER 4
ATYPICAL PKCS PROMOTE CELL DIFFERENTIATION, SURVIVAL OF
MELANOMA CELLS VIA NF-κB AND PI3K/AKT PATHWAYS

4.1 Introduction
Phosphatidylinositol 3-kinase and Protein Kinase B (PI3K/AKT) and nuclear factor kappa-lightchain-enhancer of activated B (NF-κB) pathways are frequently hyper-activated in various
carcinomas thereby promoting cellular growth, differentiation and survival (152). As we discussed
in Chapter 1, overexpression of aPKCs is often associated with anti-apoptotic effects in many
cancers.
The NF-κB transcription factor family was discovered in 1986. It often plays a complex and
essential role in inflammation and immune response. NF-κB is also well-known for human cancer
initiation, progression and poor prognosis (153,154). The NF-κB family consists of five members;
p65 (RelA), RelB, c-Rel, NF-κB1 (p105/p50) and NF-κB2 (p100/p52) (152,155–158). These
subunits can form a variety of homodimers or heterodimers, which are essential for NF-κB
activation, crosstalk and translocation to the nucleus. Heterodimer between p65 (RelA) and p50
NF-κB subunits is the most important complex in the NF-κB family. In many quiescent cells these
dimers are bound to a family of inhibitory proteins molecules called “inhibitors of NF-kB” (IκB)
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(157). IκB proteins contain ankyrin repeats, which bind with the DNA binding domains of the NFκB transcription factors making them transcriptionally inactive (157).
Both the canonical and non-canonical NF-κB pathways are upregulated in many carcinomas.
Activating mutations in NF-κB genes were first reported in B-cell lymphoid malignancies (159).
Mutations of upstream signaling molecules such as RAS superfamily, epidermal growth factor
receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) often lead to
hyperactivation of NF-κB (160). Additionally, continuous release of cytokines by macrophages in
the tumor microenvironment also leads to an upregulation of NF-κB (157). Outcomes of such
hyperactivations of NF-κB strictly depends on the cell type or the tumor microenvironment. The
human immune system can play a dual role by being either tumor-promotive, which leads to more
aggressive tumors, or host-protective. Upregulated NF-κB promotes cell survival by inhibiting
apoptosis through stimulating the transcription of anti-apoptotic genes (161). This provides
support to survive the physiological stress during inflammation, thereby playing an important role
in the initiation of tumors (157,162). NF-κB also upregulates the transcription of proliferation
regulating genes such as cyclin D1 and C-MYC (163,164). Additionally, NF-κB upregulates
metastasis by altering cellular adhesion molecules and matrix metalloproteinases. NF-κB also
upregulates the VEGF dependent angiogenesis (165). The tumor microenvironment of solid
tumors often contain elevated levels of inflammatory cytokines and hypoxic conditions, which can
elevate the activation and nuclear translocation of NF-κB (158,166). NF-κB can also induce the
expression of activation-induced cytodine deaminase (AID) and APOBEC ("apolipoprotein B
mRNA editing enzyme, catalytic polypeptide-like") proteins. The AID/APOBEC family is an
important contributor to cancer development and clonal evolution of cancer by inducing collateral
genomic damage (154).
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On the other hand the PI3K/AKT pathway is also an actively pursued therapeutic target in
oncology. Upregulation of PI3K/AKT pathway appears to be characteristic of many aggressive
cancers, which activates numerous survival, growth, metabolic and metastatic functions. Once
activated, PI3K catalyzes the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) to
produce phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 activates intracellular signaling
through its binding to pleckstrin homology (PH) domains of many signaling proteins, including
AKT (167,168). Activated AKT phosphorylates and activates many oncogenic features within
cancer cells. The mammalian target of rapamycin (mTOR) is a major downstream signaling
protein, which is activated by AKT. mTOR is involved in protein translation via the eukaryotic
translation initiation factor 4E (eIF4E) complex and ribosomal protein S6 kinase (S6K). Both
mTOR and S6K are hyperactivated in prostate cancer due to upregulated AKT (169). AKT
promotes cellular survival by inhibiting pro apoptotic Bcl-2 family members such as BAD and
BAX (170). Furthermore, AKT deactivates the tumor suppressor forkhead box protein O1
(FOXO1).
PI3K/AKT pathway activates the NF-κB pathway, wherein aPKCs play a role in releasing NF-κB
complex to translocate to the nucleus and promote cellular growth and survival. Win et al. reported
that PKC-ζ actively upregulates the activation of NF-κB nuclei translocation thereby inducing
cancer cell survival in prostate cancer cells (80). In addition, PI3K stimulates IκB kinase (IKKα/β)
through activation of AKT by phosphorylation at S473 or S463, which ultimately stimulates
translocation of NF-κB complex into the nucleus, heightening cell survival (171). Phosphatase and
tensin homolog (PTEN) regulates the levels of PI3K. Phosphorylation at S380 leads to the
inactivation of PTEN, thereby increasing the levels of PI3K followed by enhancement in
phosphorylated AKT (S473/S463).
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Here, we present our data for the analysis of PI3K/AKT and the NF-κB pathways. We have tested
how NF-κB and AKT are affected by aPKC inhibition during five aPKC inhibitor applications.
We tested the levels of PTEN, phosphorylated PTEN (S380), phosphorylated AKT (S473), IKBα
and phosphorylated IKBα, phosphorylated IKKα/β (S176/180), NF-κB p65 in cytoplasm and in
nucleus for SK-MEL-2 and MeWo melanoma cell lines. Our data indicates that inhibition of PKCι and PKC-ζ significantly decreased the levels of phosphorylated PTEN and phosphorylated AKT
compared to control samples (142). This indicates that PKC-ζ and PKC-ι may upregulate the
PI3K/AKT pathway to induce cellular survival of melanoma cells. Additionally, we tested the
levels of NF-κB translocation by separating the nuclear extracts from the cell lysates to observe
how NF-κB activation process alters upon aPKC inhibition in relation to the levels of inhibitor of
kappa B (IκB), phosphorylated IκB (S32) and phosphorylated IKKα/β (S176/180). Our data also
demonstrate the effects of tumor necrosis factor alpha (TNF-α) stimulation on the expression of
aPKCs in relation to PI3K/AKT mediated NF-κB. TNF-α is a cytokine, involved in the early phase
of acute inflammation by activating NF-κB pathway. This information is important for the proper
understanding of the aPKC role in melanoma progression.

4.2 Results
4.2.1 Western blot analysis of AKT and the NF-κB pathways post aPKC specific inhibitor
treatment
We started the analysis with a more general approach by testing ACPD and DNDA on normal
melanocytes against melanoma cell lines since ACPD and DNDA specifically bind to both aPKCs
and demonstrated inhibitive properties (143). Western blots were performed to investigate the
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effects of ACPD and DNDA on the expression of aPKCs, apoptotic markers, AKT and NF-κB on
malignant melanoma cell lines (Fig. 4.1 and 4.2). IC50 concentration of ACPD significantly
reduced the PKC-ι level by 43% and by 31% of phosphorylated PKC-ι (T555) in SK-MEL-2 cell
line and by 46% of PKC-ι and 26% of phospho PKC-ι (T555) in MeWo cells. DNDA significantly
decreased the levels of PKC-ι by 52%, phospho PKC-ι (T555) by 33% in SK-MEL-2 and by 27%
of PKC-ι and phospho PKC-ι (T555) by 20% in MeWo cells. Also, ACPD significantly reduced
the PKC-ζ level by 42% and by 29% of phospho PKC-ζ (T410) in SK-MEL-2 cell line and by 42%
of PKC-ζ and 23% of phospho PKC-ζ (T410) in MeWo cells. DNDA significantly reduced the
levels of PKC-ζ by 33%, phospho PKC-ζ (T410) by only 17% in SK-MEL-2 and by 60% of PKCζ and phospho PKC-ζ (T410) by 29% in MeWo (143).
In terms of apoptotic markers, treatments of the inhibitors led to significantly increased Caspase3 levels (26% and 17%) in ACPD treated SK-MEL-2 and MeWo cells, respectively. Caspase-3
levels significantly increased by 32% and 39% in DNDA treated SK-MEL-2 and MeWo cells,
respectively. Poly (ADP-ribose) polymerase (PARP) levels significantly decreased by 33% and by
24% in ACPD treated SK-MEL-2 and MeWo cells, respectively, while cleaved-PARP levels
significantly increased by 14% and 18%, respectively. In DNDA treated samples, PARP levels
significantly decreased by 12% and by 9% in SK-MEL-2 and MeWo cells, respectively, while
cleaved-PARP levels significantly increased by 16% and 10%, respectively. Similarly, Bcl-2
levels significantly decreased by 13% and by 25% in ACPD treated SK-MEL-2 and MeWo cells,
respectively, while in DNDA treated cells Bcl-2 levels decreased by 7% and by 32% in SK-MEL2 and MeWo cells, respectively. PTEN levels significantly increased by 44% and 55% in ACPD
treated SK-MEL-2 and MeWo cells, respectively, compared to 68% and 48% increases in DNDA
treated samples while respective phospho AKT (S473) levels showed a reduction. However, NF-
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κB p65 levels were significantly heightened by 31% and 69% in ACPD treated SK-MEL-2 and
MeWo cells, and there were 49% and 89% increases in DNDA treated samples. All values
(percent) were calculated and compared to their respective control in WB (Fig 4.2; densitometry
analysis) and significance was indicated as P≤0.05. β-actin was used as the internal control to
ensure that equal amounts of proteins were loaded in each lane in the sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE) (143).
To establish the specific roles of both PKC-ι and PKC-ζ on melanoma progression, we
subsequently used ICA-1T, ICA-1S and ζ-Stat to specifically inhibit PKC-ι and PKC-ζ in
melanoma cells. A detailed analysis was conducted for aPKC expression, aPKC phosphorylation,
activation of AKT and NF-κB pathway through Western blot analysis. As shown in Figure 4.3,
Western blots revealed that both ICA-1T and ICA-1S significantly reduced total and
phosphorylated PKC-ι while having no effect on PKC-ζ. ζ-Stat showed a significant diminution of
phosphorylated and total PKC-ζ levels. Since all inhibitors significantly reduce melanoma cell
proliferation, we tested the potential of the inhibitors on inducing the apoptosis. Caspase-3 and
cleaved-PARP levels were significantly increased and Bcl-2 and PARP levels were significantly
diminished upon inhibitor treatments. These results reconfirmed the apoptotic stimulation upon
inhibition of PKC-ι and PKC-ζ using specific inhibitors. We also tested the levels of β-catenin,
phosphorylated PTEN (S380), phosphorylated AKT (S473), IKBα and phosphorylated IKBα,
phosphorylated IKKα/β (S176/180), NF-κB p65 in cytoplasm and in nucleus. β-catenin levels did
not change significantly while phospho PTEN, phospho AKT, phospho IKBα, phospho IKKα/β
and nucleic NF-κB p65 significantly decreased and levels of IKBα and cytoplasmic NF-κB p65
significantly increased as a result of the three inhibitors. Figure 4.4 shows the densitometry
analysis for said markers for ICA-1T, ICA-1S and ζ-Stat treatments.
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Additionally, we tested the effects of TNF-α and TGFβ stimulation on aPKC expression in relation
to AKT and NF-κB pathways. As shown in Figure 4.5 and 4.6, we found that protein levels and
the degree of phosphorylation significantly increased for both aPKCs in the presence of TNF-α,
thereby significantly heightening phosphorylation on PTEN (S380), AKT (S473), IKKα/β
(S176/180), IKBα (S32) and Vimentin (S39) which resulted in enhancing Bcl-2, NF-κB
translocation. Furthermore, PKC-ι was upregulated as a result of TGFβ treatments and no
significant change was observed for PKC-ζ levels for TGFβ treatments. This indicates that TNFα upregulate the aPKCs in relation to NF-κB and AKT pathways which result in cellular survival
and rapid growth in melanoma cells.
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Figures 4.1-4.2. Western blots of the effects of ACPD and DNDA on aPKC expression and
apoptosis on malignant melanoma cells. Fig. 4.1 represents the expression of phosphorylated PKCι, total PKC-ι, phosphorylated PKC-ζ, total PKC-ζ and apoptotic markers (Caspase-3, cleaved
PARP, total PARP and Bcl-2) for the ACPD and DNDA (2.5 µM) treated malignant melanoma
cell lines (SK-MEL-2 and MeWo) after the end of the 3rd day of treatments with respect to their
controls. Fig. 4.2 indicates the densitometry values of 4.1 Western blots which are shown as the
percentage change of the treated samples with respect to their controls and Mean ± SD are plotted.
40 µg of protein was loaded in to each well and β-actin was used as the loading control in each
Western blot. Experiments (N=3) were performed.
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Figures 4.3-4.4: Effect of ICA-1S, ICA-1T and ζ-Stat on aPKC expression, apoptosis, and
signaling pathways related to NF-κB and PI3K/AKT pathways in melanoma cells. Expression of
the protein levels of phosphorylated PKC-ι, total PKC-ι, phosphorylated PKC-ζ, total PKC-ζ,
Caspase-3, cleaved PARP, total PARP, Bcl-2, β-catenin, phosphorylated PTEN, RhoA,
phosphorylated AKT and NF-κB p65, IκB, phosphorylated IκB and phosphorylated IKKα/β for
the inhibitor treatments (2.5 µM of ICA-1S, 1 μM of ICA-1T and 5 μM of ζ-Stat) are shown in
Fig. 4.3. 40-80 µg of protein was loaded in to each well and β-actin was used as the loading control
in each Western blot. Fig. 4.4 represents the densitometry values for Western blots in Fig. 4.3.
Experiments (N=3) were performed in each trial and representative bands are shown.
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Figures 4.5-4.6: Effect of TNF-α and TGFβ on aPKC expression, apoptosis, and signaling
pathways related to NF-κB and PI3K/AKT pathways in melanoma cells. Expression of the protein
levels of phosphorylated PKC-ι, total PKC-ι, phosphorylated PKC-ζ, total PKC-ζ, Caspase-3,
cleaved PARP, total PARP, Bcl-2, β-catenin, phosphorylated PTEN, RhoA, phosphorylated AKT
and NF-κB p65, IκB, phosphorylated IκB and phosphorylated IKKα/β for the the TNF-α (20
ng/ml) and TGFβ (250 pg/ml) treatments are shown in Fig. 4.5 for malignant melanoma cell lines
(SK-MEL-2 and MeWo). 40-80 µg of protein was loaded in to each well and β-actin was used as
the loading control in each Western blot. Fig. 4.6 represents the densitometry values for Western
blots in Fig. 4.5. Experiments (N=3) were performed in each trial and representative bands are
shown.
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4.3 Summary
Our Western blots data revealed that both ICA-1T and ICA-1S significantly reduced total and
phosphorylated PKC-ι while having no effect on PKC-ζ. ζ-Stat showed a significant diminution
of phosphorylated and total PKC-ζ levels without showing a significant effect of PKC-ι. On the
other hand, both ACPD and DNDA showed specificity towards both aPKC isoforms. These data
confirmed the kinase activity assay data and molecular docking predictions we reported in the
previous chapter. As we demonstrated in Chapter 3, all inhibitors significantly reduce melanoma
cell proliferation without showing a significant effect on normal melanocytes at IC50
concentrations. Therefore, here we tested the potential of the inhibitors to induce the apoptosis at
the same concentrations.
As demonstrated in Figures 4.1 and 4.3, cleaved-PARP levels were significantly increased while
Bcl-2 and PARP levels were significantly diminished upon inhibitor treatments. Increase in
Caspase-3, increase in PARP cleavage, and decrease in Bcl-2 all indicate apoptosis stimulation
(172–175). Increase in Caspase-3 levels is not always a direct indication of inducing apoptosis due
to the tight binding of cleaved Caspase-3 with X-linked inhibitor of apoptosis protein (XIAP).
XIAP undergoes auto-ubiquitination, but this process delays apoptosis until all XIAP is removed
(176). Owing to this, we also tested direct PARP and cleaved PARP levels because PARP is a
known downstream target for Caspase-3. PARP cleaves more upon inducing the apoptosis. We
also tested Bcl-2 levels since it inhibits Caspase activity by preventing Cytochrome c release from
the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1) (177). All five
inhibitor treatments depicted an increase in apoptotic activity in both SK-MEL-2 and MeWo cell
lines. This data confirms that aPKCs have an anti-apoptotic effect.
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One major anti-apoptotic pathway is NF-κB activation, which entails aPKC releasing NF-κB and
NF-κB translocates to the nucleus to promote cell survival (178). Interestingly, aPKC inhibition
increased the NF-κB production in both cells even though we observed an apoptotic stimulation.
This was evident in the cytosolic NF-κB levels shown in Figures 4.3 and 4.4. But data shows a
downregulation of AKT pathway which was evident from elevated levels of PTEN and lower
levels of phospho AKT (S473), which agreed with apoptotic stimulation upon aPKC inhibition. In
order to investigate further, we tested the effects of ICA-1T, ICA-1S and ζ-Stat on SK-MEL-2 and
MeWo cell lines which provided specific inhibition of PKC-ι with ICA-1T and ICA-1S and the
PKC-ζ inhibition with ζ-Stat. To interpret the fate of NF-κB pathway, we separated cytosol and
nuclei and analyzed them separately. Figure 4.3 demonstrated that inhibition of PKC-ι and PKCζ expressively decreased the levels of phosphorylated PTEN and phosphorylated AKT (142). This
specifies that PKC-ζ and PKC-ι may upregulate the PI3K/AKT pathway to induce cellular survival
of melanoma cells. Our data demonstrated that aPKCs play a role in releasing NF-κB to translocate
to the nucleus and promote cell survival in melanoma cells. PI3K stimulates IKKα/β through
activation of AKT by phosphorylation at S473, which ultimately stimulates translocation of NFκB complex into the nucleus, boosting cell survival (171). PTEN regulates the levels of PI3K.
Phosphorylation at S380 leads to the inactivation of PTEN, thereby increasing the levels of PI3K
followed by enhancement in phospho-AKT. Inhibition of PKC-ι and PKC-ζ significantly
decreased the levels of phospho-PTEN and phospho-AKT but we still found increases in NF-κB
p65 levels in the cytosol after inhibiting both aPKCs. This may seem illogical, but previous studies
have shown that expression of NF-κB p65 has a corresponding increase in IκB, resulting in an
auto-regulatory loop (171). Moreover, negative feedback is not inhibiting upstream signaling for
NF-κB translocation because translocation has been inhibited downstream, resulting in more NF-
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κB production. Knowing this, we tested the levels of NF-κB translocation by separating the nuclear
extracts from the cell lysates and found that NF-κB levels in the nuclei decreased upon aPKC
inhibition. This suggested that translocation of activated NF-κB in to nuclei is inhibited as a result
of inhibition of aPKCs. Furthermore, we also found that aPKC inhibition increased the levels of
IκB while decreasing the levels of phosphorylated IκB (S32) and phosphorylated IKKα/β
(S176/180), confirming that both PKC-ι and PKC-ζ play a role in phosphorylation of IKKα/β and
IκB: increased levels of IκB therefore remain bound to NF-κB complex and prevent the
translocation to the nucleus to promote cell survival. As summarized in Figure 4.7, our data also
demonstrate the effects of TNF-α stimulation on the expression of aPKCs. TNF-α is a cytokine,
involved in the early phase of acute inflammation by activating NF-κB. TNF-α stimulation
significantly increased NF-κB levels in both cytosol and nuclei. Increased NF-κB production
promotes increases in total and phosphorylated aPKCs and increased the levels of Bcl-2, which
enhanced melanoma cell survival. We observed amplified levels of IκB and NF-κB, which together
enhanced the phosphorylation of IκB due to the augmented levels of aPKCs. On the other hand,
PI3K/AKT signaling can be diminished by inhibiting aPKCs via downregulation of NF-κB. These
results confirm that both PKC-ζ and PKC-ι are rooted in cellular survival via NF-κB and
PI3K/AKT pathways.
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Figure 4.7: A schematic summary of the involvement of PKC-ι and PKC-ζ in melanoma
progression via NF-κB and PI3K/AKT pathways. Upon extracellular stimulation with TNF-α,
activation of AKT through PIP3 takes place as a result of inactivation of PTEN. Activated AKT
pathway can lead to cell survival, rapid proliferation and differentiation which are critical parts of
melanoma progression. AKT could indirectly stimulate NF-κB pathway along with PKC-ι and
PKC-ζ in which they play a stimulatory role on IKK-α/β in order to promote the releasing the NFκB complex from IκB to translocate into nucleus.

52

CHAPTER 5
PKC-ι PROMOTES METASTASIS OF MELANOMA CELLS BY PROMOTING
EPITHILIAL-MESENCHYMAL TRANSITION (EMT) AND ACTIVATING VIMENTIN

5.1 Introduction
Epithelial-mesenchymal transition as well as its reverse process mesenchymal-epithelial transition
(MET), is essential for development and physiological response to an injury (such as wound
healing) as well as in carcinogenesis (179,180). Under normal conditions, epithelial cells are linked
together and the extracellular matrix (ECM) environment by different types of intercellular
junctions such as desmosomes, adherens, and tight junctions, which enable tissue maintenance and
stability (181). Epithelial cells can gain the ability to acquire a mesenchymal phenotype allowing
for physiological circadian tissue changes but also for tissue loss or damage (182). Interestingly,
this process is also associated with an transformation to intermediate stem cell phenotype, thus
reflecting the highly conserved mechanisms during embryogenesis (179,183).
EMT represents the intersection of different aspects of human development which are sequential
rather than parallel processes (181). During the early phase of human development, EMT is
involved in morphogenesis and stem cell plasticity required for correct implantation, gastrulation
and organogenesis (184,185). In the adult organism, subsequent processes relying on regulated
EMT or MET are tissue maintenance allowing for reconstruction or maintenance of tissue, as well
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as cell homeostasis after inflammatory or degenerative insults. In the case of chronic inflammatory
and degenerative diseases, such as organ fibrosis, the EMT/MET system is over-regulated which
may lead to organ insufficiency or failure (186–188).
EMT plays a key role in the initial steps of tumor cell dissemination and metastasis. Typically,
EMT is found locally at the tumor front with a characteristically increased expression of vimentin
paralleled by a loss of E-cadherin (189,190).
Throughout EMT, epithelial cells lose apical-basal polarity, remodel the extracellular matrix
(ECM), rearrange the cytoskeleton, drive changes in signaling programs that control the cell shape
maintenance and adapt gene expression to obtain mesenchymal phenotype, which is invasive and
increases individual cell motility (191). EMT’s key features comprise downregulation of Ecadherin to destabilize tight junctions between cells and upregulation of genes such as Vimentin
that may assist mesenchymal phenotype.
Migration and invasion studies in cancer research are very important because the main cause of
death in cancer patients is related to metastatic progression. For cancer cells to spread and
distribute throughout the body, they must migrate and invade through ECM, undergo intravasation
into blood stream and extravasation to form distant tumors. EMT is the driving force of this
phenomenon (190).
Vimentin is a very important structural protein that belongs to the family of type III intermediate
filament proteins. Intermediate filaments (IFs) make up a vast network of interconnecting proteins
between the plasma membrane and the nuclear envelope and convey molecular and mechanical
information between the cell surface and the nucleus. IF protein expression is cell type and tissue
specific. Mesenchymal cells, fibroblasts, lymphocytes and most types of tumor cells express
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Vimentin (192,193). Vimentin is essential for organizing microfilament systems, changing cell
polarity, and thereby changing cellular motility. Moreover, increased Vimentin expression during
EMT is a hallmark of metastasis which plays a very important role in gaining rear-to-front polarity
for transforming epithelial cells. In addition to EMT, Vimentin expression is observed in cell
mechanisms involved in cellular development, immune response and wound healing
(142,143,194).
Vimentin is activated via phosphorylation and various kinases such as; RhoA kinase, protein
kinase A, PKC, Ca2+/calmodulin-dependent protein kinase II (CaM kinase II), cyclin-dependent
kinase 1 (CDK1), RAC-alpha serine/threonine-protein kinase (AKT1) and RAF proto-oncogene
serine/threonine-protein kinases (Raf-1-associated kinases) are known to play a role in regulation
of Vimentin via phosphorylation. Studies show that amino acid sites S6, S7, S8, S33, S39, S56,
S71, S72, and S83 amongst others, serve as specific phosphorylation sites on the head region of
Vimentin (195–203).
Zinc finger protein SNAI1 (SNAIL1) and paired related homeobox 1 (PRRX1) are two very
important transcription factors (TFs) which regulate EMT and we show that activated PKC-ι is
being regulated via these TFs in relation to Vimentin in melanoma cells. The changes in gene
expression that contribute to the repression of the epithelial phenotype and activation of the
mesenchymal phenotype involve PRRX1 and SNAIL1. Their expression is activated early in
EMT, and they have central roles in the progression of cancer. As these transcription factors have
distinct expression profiles, their contributions to EMT depend on the cell or tissue type involved
and the signaling pathways that initiate EMT. During EMT, these cells downregulate the
expression of cell junction complex proteins such as E-cadherin (204). They also alter their gene
expression program to promote mesenchymal behavior. SNAIL1 and PRRX1 are two known TFs
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that upregulate Vimentin (205,206). They often control the expression of each other and
functionally cooperate at targeted genes, and with additional transcription factors to further define
the EMT transcription program that drives EMT progression.

5.2 Results
5.2.1 PKC-ι promotes migration and invasion of melanoma cells; a comparative study
based on atypical PKC inhibitors
Wound healing assay was performed using ACPD and DNDA in the initial stage to investigate the
effect of both PKC-ι and PKC-ζ on malignant melanoma cell migration in-vitro. Wound healing
assay is commonly used to investigate in-vitro migration of cancer cells (207). Photographs for
each cell line are compared as “day 0” (starting point) and “day 3” or “day 4” for both malignant
cell lines (Fig. 5.1). Cells treated with ACPD 2.5 µM and DNDA 2.5 µM were compared with
their respective controls. The areas of the scratch (wound) were calculated and compared to
determine the statistical significance (Fig. 5.2). We found that both inhibitors significantly reduce
the wound closure (P≤0.01) of both cell lines compared to their respective controls.
Basement membrane extract (BME) invasion assay was performed to investigate the effect of
ACPD and DNDA on malignant melanoma cell invasion in-vitro. Although it is similar to Boyden
chamber assay, it avoids scraping off the Matrigel and staining to assess the number of migrated
cells through the filter. Hence, the method carries less human error compared to a conventional
Boyden chamber assay (208). As demonstrated in Figures 5.3 and 5.4, invasion was significantly
reduced (P≤0.05) by 24% and 21% in ACPD (2.5 µM) treated SK-MEL-2 and MeWo cells
compared to its control. In DNDA (2.5 µM) treated samples, the invasion was significantly reduced
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(P≤0.05) by 32% in both SK-MEL-2 and MeWo cell lines compared to its control. These data
suggested that either inhibition of PKC-ζ and PKC-ι or both significantly retard the cellular
migration and invasion of melanoma. Since ACPD and DNDA target both aPKCs it was not
conclusive about specific impact of inhibition of PKC-ι and PKC-ζ on melanoma cell migration
and invasion. Because of this, we later used ICA-1T, ICA-1S and ζ-Stat since they specifically
inhibit aPKCs as explained before.
As shown in Figures 5.5 and 5.6, compared to 80% wound closure in SK-MEL-2 control, inhibitor
treated samples showed fewer wound closures as 28% (P≤0.01) for ICA-1T at 1 µM, 33% (P
≤0.01) for ICA-1S at 2.5 μM and 53% (P ≤0.05) ζ-Stat at 5 µM. Compared to 66% wound closure
in MeWo control, inhibitor treated samples were 26% (P ≤0.01) for ICA-1T at 1 µM, 32% (P
≤0.01) for ICA-1S at 2.5 μM and 54% (P ≤0.05) ζ-Stat at 5 µM. Results suggested inhibition of
PKC-ι is more effective in reducing cell migration in-vitro compared to PKC-ζ. Similarly, BME
invasion assay was performed to investigate the effects of ICA-1S, ICA-1T and ζ-Stat on
melanoma cell invasion in-vitro. Invaded cells adhered on the bottom surface of transwell inserts
were stained with crystal violet and photographs were taken in randomly chosen fields as the visual
representation of the invasion assay (Fig. 5.7). Crystal violet stained invaded cells were dissolved
in 70% ethanol in the bottom chamber and absorbance was measured at 590 nm which is
proportional to the number of invaded cells (Fig. 5.8). ICA-1T and ICA-1S significantly (P ≤0.01)
reduced invasion by 55% and 43% in SK-MEL-2 cells and by 48% and 44% in MeWo cells,
respectively. Interestingly, ζ-Stat did not show a significant effect on decreasing melanoma cell
invasion. These data showed that PKC-ι inhibition showed a significant reduction of both
melanoma cellular migration and invasion while PKC-ζ inhibition did not show any effect on
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cellular invasion. These results confirmed that PKC-ι plays a crucial role in cellular migration and
invasion over PKC-ζ in melanoma.

Figures 5.1-5.4: ACPD and DNDA decrease melanoma cell migration and invasion. Figure 5.1
and 5.2 represent the effect of aPKC inhibitors (2.5 µM of ACPD and DNDA) on melanoma cell
migration in wound healing assay and Figure 5.3 represents the effect of inhibitors on melanoma
cell invasion in Boyden chamber assay with basement extract. In wound healing assay,
microscopic photographs of scratches on cells at the beginning (day 0) were compared with the
photographs taken after 3 or 4 days. The effect of inhibitors are shown (Fig. 5.1) compared to their
control for both ACPD and DNDA. Experiments (N=3) were performed for each cell line and
randomly picked photographs are shown. Figure 5.2 represents a comparison of calculated percent
wound closure for the photographs taken. For Boyden chamber assay (Fig. 5.3), relative
fluorescence unit (RFU) values were reported after 2 h exposure of invaded cells with CalceinAM, as a comparison of control and inhibitors (2.5 µM ACPD and DNDA) treated samples by
subtracting the blanks (no cells). Figure 5.4 shows representative photographs of invaded cells
after a three day incubation period. Mean ± SD are plotted. Statistical significance is indicated by
asterisk as **P< 0.01.
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Figures 5.5-5.8: ICA-1S, ICA-1T and ζ-Stat decrease melanoma cell migration and invasion. Fig.
5.5 and 5.6 represent the effect of aPKC inhibitors (2.5 µM of ICA-1S, 1 μM of ICA-1T and 5 μM
of ζ-Stat) on melanoma cell migration in wound healing assay and Figure 5.7 and 5.8 represent the
effect of inhibitors on melanoma cell invasion in Boyden chamber assay with basement extract
(BME). In the wound healing assay, microscopic photographs (40×) of scratches on cells at the
beginning (day 0) were compared with the photographs taken after 3 days. The effect of inhibitors
are shown (Fig. 5.5) compared to their controls. Experiments (N=3) were performed for each cell
line and randomly picked photographs are shown. Figure 5.6 represents a comparison of calculated
percent wound closure for the photographs taken using ImageJ (NIH, Rockville, MD, USA). For
Boyden chamber assay (Fig. 5.7), invaded cells in the bottom surface of transwell insert were
stained with 0.5% crystal violet and microscopic pictures were taken (100×). Subsequently, crystal
violet was dissolved in 70% ethanol and absorbance was measured at 590 nm, which is directly
proportional to the number of invaded cells. These absorbency values are included in Figure 5.8.
Mean ± SD are plotted. Statistical significance is indicated by asterisk as **P< 0.01.

Our preliminary data showed that Vimentin was not detected in normal melanocytes compared to
higher levels in melanoma cells, which was similar to the expression pattern of PKC-ι in these cell
lines as we demonstrated in Figure 2.1 We have already shown that both ICA-1T and ICA-1S
significantly reduced total and phosphorylated PKC-ι while having no effect on PKC-ζ. On the
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other hand, ζ-Stat showed a significant diminution of phosphorylated and total PKC-ζ levels
without affecting PKC-ι levels. Therefore, since these inhibitors were effectively inhibiting their
targets, we also investigated the effects of aPKC inhibition on EMT signaling to understand how
specific aPKC inhibition alters EMT stimulation in melanoma cells. We tested the levels of Ecadherin, phosphorylated Vimentin (S39), total Vimetin, Par6 and RhoA (Fig. 5.9 and 5.10).
Interestingly, inhibition of PKC-ζ using ζ-Stat showed no significant effect on E-cadherin,
Vimentin and phospho-Vimentin or Par6 and RhoA. Conversely, ICA-1T and ICA-1S inhibition
on PKC-ι resulted in a significant increase of E-cadherin and RhoA while significantly decreasing
Vimentin, phospho-Vimentin and Par6 (Fig. 5.9 and 5.10).
To fully establish these observations, we used siRNA for PKC-ι and PKC-ζ to knockdown the
expression of the target proteins and subsequently investigated the levels of protein expression for
the proteins E-cadherin, phosphorylated Vimentin (S39), total Vimetin, Par6 and RhoA (Fig. 5.11
and 5.12). These experiments showed a complementary situation for our inhibitor applications for
the targeted proteins. Scrambled siRNA was also used in addition to the control and there was no
significant difference observed between the control and scrambled siRNA treatments for the said
proteins.
siRNA treatments of PKC-ι resulted in significant decrease in PKC-ι level by 87% and 64% in
SK-MEL-2 and MeWo cell lines, respectively. PKC-ζ decreased by 11% and 0%, which is not
significant, while Bcl-2 significantly decreased by 68% and 84%, Vimentin decreased by 73% and
67%, phospho Vimentin (S39) significantly decreased by 92% and 81%, E-cadherin increased by
59% and 46%, RhoA increased by 33% and 26%, and Par6 decreased by 42% and 55% in PKC-ι
siRNA treated SK-MEL-2 and MeWo cells, respectively.
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siRNA treatments of PKC-ζ resulted in significant decrease in PKC-ζ level by 83% and 76% in
SK-MEL-2 and MeWo cell lines, respectively. As expected Vimentin, phospho Vimentin, Ecadherin, Par6 and RhoA levels of PKC-ζ siRNA treated samples did not show a significant
difference to its control.

5.2.2 PKC-ι may induce EMT by upregulating TGFβ/Par6/RhoA and SMAD pathways
Earlier in Chapter 4, the effects of TNF-α and TGFβ stimulation on aPKC expression were
demonstrated (Fig. 4.5 and 4.6). These experiments showed that both TNF-α and TGFβ upregulate
PKC-ι while TGFβ did not increase the production of PKC-ζ.
As shown in Figures 5.13 and 5.14, we found that levels of Vimentin, Par6 and the degree of
phosphorylation of Vimentin (S39) significantly increased for both cell lines in the presence of
TGFβ while reducing the levels of E-cadherin and RhoA.
So far these results showed a strong relationship of PKC-ι with the melanoma cell migration and
invasion over PKC-ζ. Whenever PKC-ι is inhibited or knocked down in its expression, melanoma
cell motility decreased. In addition, it shows that PKC-ι inhibition leads to decreased mesenchymal
markers; Vimentin and Par6 increase the expression of epithelial markers; E-cadherin and RhoA.
These observations indicate a possible slowing down or reversing the EMT progression of
melanoma cells upon PKC-ι diminution. Interestingly, Vimentin show a very strong relationship
with PKC-ι as indicted in the Western blot analysis for inhibitor treatments (Fig. 5.9) and siRNA
treatments (Fig. 5.11). Also data strongly suggest that PKC-ι inhibition effects the phosphorylation
of Vimentin (S39), which is a crucial site for elevated Vimentin dynamics. Data shows that
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Vimentin activity decreases as a result of PKC-ι diminution. On the other hand PKC-ζ did not
show any involvement with the EMT process or Vimentin dynamics.

Figures 5.9-5.12: Effect of inhibitors (ICA-1S, ICA-1T and ζ-Stat) and siRNA knockdown of the
expression of aPKCs on aPKC expression and EMT in melanoma cells. Expression of the protein
levels of PKC-ι and PKC-ζ were depleted confirming the accuracy of siRNA. Protein levels of
Vimentin, phosphorylated Vimentin, Par6, RhoA and E-cadherin are shown for the inhibitor
treatments (2.5 µM of ICA-1S, 1 μM of ICA-1T and 5 μM of ζ-Stat) and for and for siRNA
treatments are shown in Fig. 5.9 and 5.11, respecively. 40 µg of protein was loaded in to each well
and β-actin was used as the loading control in each Western blot. Figures 5.10 and 5.12 represent
the densitometry values for Western blots shown in 5.9 and 5.11, respectively. Experiments (N =
3) were performed in each trial and representative bands are shown.
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Figures 5.13-5.14: Effect of TNF-α and TGFβ on aPKC expression and EMT in melanoma cells.
Protein levels of Vimentin, phosphorylated Vimentin, Par6, RhoA and E-cadherin are shown for
the TNF-α (20 ng/ml) and TGFβ (250 pg/ml) treatments are shown in Fig. 5.13. 40 µg of protein
was loaded in to each well and β-actin was used as the loading control in each Western blot. Figure
5.14 represents the densitometry values for Western blots shown in 5.13. Experiments (N = 3)
were performed in each trial and representative bands are shown.

5.2.3 PKC-ι associates with Vimentin and play a critical role in upregulation of Vimentin
dynamics in melanoma cells
To investigate the relationship of PKC-ι and Vimentin, an immunoprecipitation (IP) experiment
was conducted. PKC-ι and PKC-ζ were separately immunoprecipitated (IP) and Western blot
experiments were conducted independently for E-cadherin, CD44, Vimentin and NF-κB p65
(143). PKC-ζ IP samples did not show any association with these proteins. Only Vimentin
immunoblots showed an association with PKC-ι IP samples (Fig. 5.15). This suggests that PKC-ι
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associates with Vimentin. To confirm this association, Vimentin was immunoprecipitated,
immunoblotted for above mentioned proteins, and only PKC-ι demonstrated an association with
Vimentin. Both these IP and reverse IP of PKC-ι and Vimentin showed a strong direct association
between them (Fig. 5.15 and 5.16). An association was essential between Vimentin and PKC-ι for
PKC-ι to phosphorylate Vimentin.
Figures 5.17 and 5.18 show immunofluorescence staining studies, which also confirmed the
association of PKC-ι and Vimentin depicting both proteins distributed throughout the cytoplasm.
ICA-1T treated cells showed lesser amounts of those proteins (lighter in staining) compared to
control samples. Inhibitor treatments for both cell lines also decreased the nuclei and overall cell
sizes. In the controls of both cells, the invasive characteristics such as formation of lamellipodia,
filopodia and invadopodia are observable clearly whereas ICA-1T treated cells showed less of
such features.
Figures 5.19-5.28 demonstrate RT qPCR data, which revealed that PKC-ι mRNA levels decreased
upon having been treated with ICA-1T and ICA-1S, by approximately 50% in SK-MEL-2 cells
and 30% in MeWo cells. There was no significant difference observed between the inhibition of
PKC- ι by ICA-1T and ICA-1S. Vimentin mRNA levels decreased by approximately 50% in SKMEL-2 cells when treated with either PKC-ι inhibitor. Vimentin mRNA levels had no significant
changes in MeWo cells treated with either ICA-1T or ICA-1S. ζ-Stat treatments had no significant
effect on Vimentin mRNA levels in either cell line.
Immunofluorescence staining revealed that the shape of melanoma cells significantly changed
upon inhibition of PKC-ι. Both Vimentin and PKC-ι levels were relatively low in ICA-1T treated
cells in comparison to their respective controls. Additionally, invasive characteristics such as
formation of lamellipodia, filopodia and invadopodia were distinctively visible in both controls,
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though they were not apparent in treated cells. This also confirmed the growth retardation observed
in melanoma cells upon aPKC inhibitor treatments that resulted in lesser growth in treated cells.
As observed in qPCR experiments, treatments with PKC-ι specific ICA-1T and ICA-1S, specific
for downregulation of PKC-ι suggested, that PKC-ι plays a role in its own regulation.
Phosphorylation of Vimentin at S39 is required for its activation, and inhibition of PKC-ι
diminishes this activation process. Very low levels of total Vimentin observed in Western blots
for ICA-1T and ICA-1S treated cells indicate that without PKC-ι, unphosphorylated Vimentin
undergoes rapid degradation. In addition to activating Vimentin, PKC-ι appears to play a role in
regulating Vimentin expression in some carcinoma cells (209,210).
The effects of PKC-ι inhibition on the Vimentin intermediate filament (VIF) dynamics were
examined in detail, while giving emphasis to the regulation of expression of Vimentin and PKC-ι.
Here we knocked down the expression of two TFs; PRRX1 and SNAIL1 using siRNA. The
changes in gene expression during EMT involve principal regulators such as SNAIL, Zinc finger
E-box-binding homeobox1 (ZEB1), Twist-related protein1 (TWIST) and PRRX1. These TFs have
highly specific expression profiles and are known to upregulate Vimentin expression during EMT
(205,206,211–214). The direct effects of downregulation of PRRX1 and SNAIL1 on PKC-ι
expression or PKC-ι activity has not been investigated before and herewith we analyze this
phenomenon since the stimulation from TGFβ has shown an increased expression of PKC-ι along
with Vimentin, as testified in the data. This observation suggested a close regulation of the
expression of Vimentin and PKC-ι in melanoma cells. Overall, the results suggested that PKC-ι is
a critical component in the regulation of Vimentin dynamics in which PKC-ι phosphorylates to
activate Vimentin, thereby leading to the disassembly of VIF to support melanoma metastasis.
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Results also indicated that PKC-ι activation and Vimentin expression regulation are interconnected
and regulated by SNAIL1 and PRRX1.
As demonstrated in Figures 5.29 and 5.30, both inhibition from ICA-1T and siRNA depletion of
PKC-ι, showed no significant effect on the PRRX1 and SNAIL1 levels. Reduction of both
phosphorylated and total PKC-ι were significant similarly shown earlier in Figures 5.9 and 5.11
which indicated that both ICA-1T and siRNA applications were effective against their specific
target PKC-ι. Depletion of PKC-ι resulted in a downregulation of total and phosphorylated
Vimentin (S39) and upregulated E-cadherin (Fig. 5.29).

5.2.4 Effects of the knockdown of expression of SNAIL1 and PRRX1 on the expression of
PKC-ι, Vimentin, E-cadherin and the activation of VIFs
Both Western blots (Fig. 5.31 and 5.32) and RT-qPCR results (Fig. 5.33-5.36) suggested that
siRNA knockdown of PRRX1 and SNAIL1 significantly reduced the expression of PKC-ι and
Vimentin and increased E-cadherin expression. As shown in Figure 5.31, siRNA of PRRX1
significantly reduced the PRRX1 expression by 90% and 93% (P≤0.05) in SK-MEL-2 and MeWo
cells, respectively. SNAIL1 expression was reduced by 92% (P≤0.05) in both cell lines in SNAIL1
siRNA treatments. Subsequently, we analyzed the effects of these knockdown of expression of
PKC-ι and Vimentin, along with the degree of phosphorylation. Phosphorylated PKC-ι (T555) was
reduced by 48% (P≤0.05), while Vimentin level was reduced by 26% (P≤0.05), for PRRX1
knocked down in SK-MEL-2 while E-cadherin expression increased by 48% (P≤0.05). On the
other hand, phosphorylated PKC-ι (T555) was reduced by 56% (P≤0.05) while Vimentin level was
reduced by 45% (P≤0.05) for SNAIL1 knocked down in SK-MEL-2 while increasing E-cadherin
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level by 37% (P≤0.05). This indicated that knockdown expression of SNAIL1 is more significant
on down regulating the levels of phospho PKC-ι (T555) and Vimentin. Interestingly, total PKC-ι
level did not change significantly. The same trend was observed in the MeWo cell line as well.
Interestingly, phosphorylation of Vimentin at S39 demonstrated more than 80% (P≤0.05)
reduction for these treatments. Previously reported data (Fig. 5.9 and 5.11) confirmed that PKC-ι
knockdown expression using PKC-ι siRNA or inhibition using ICA-1T reduced the
phosphorylation at S39. Current results also show that both PRRX1 and SNAIL1 transcriptionally
upregulate the expression of Vimentin and activated PKC-ι levels which depends on the available
amount of Vimentin. Knockdown of these TFs result a significant drop of the activated PKC-ι
(T555) without changing the total PKC-ι significantly. As far as results show, Vimentin influenced
PKC-ι regulation cycle to maintain sufficient levels of phosphorylated PKC-ι via PRRX1 and
SNAIL1. Inhibited PKC-ι provides less phosphorylated PKC-ι levels which leads to a reduction
of phosphorylated Vimentin. As a result of this negative impact upon PKC-ι inhibition on PRRX1
and SNAIL1, their transcriptional activities on Vimentin are reduced.
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Figures 5.15-5.16. PKC-ι strongly associates with Vimentin. Whole cell lysates (100 µg) of
malignant cells (SK-Mel-2 and MeWo) were IP separately for PKC-ι and Vimentin using specific
antibodies. First column of the Western blot (Fig. 5.15) represents the (+) control, which contained
40 µg of MeWo whole cell extract, applied to ensure that bands appeared for the specific proteins
in Western blots. Western blots (Fig5.15) of PKC-ι IP showed an association with Vimentin while
no association was observed for E-cadherin, CD44 and NF-κB p65. Vimentin IP confirmed the
association with PKC-ι in the Western blot while no association was observed with the above
mentioned proteins. Experiments (N=3) were performed in each trial. Densitometry for each band
was indicated in the bar graph in Fig. 5.16.
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Figures 5.17-5.18: PKC-ι and Vimentin immunofluorescence in melanoma cells for ICA-1T
treatments. Fig. 5.17 and 5.18 represents the immunofluorescence staining of nuclei (blue panel),
PKC-ι (green panel) and Vimentin (red panel) for SK-MEL-2 and MeWo cells treated with ICA1T (1 μM) against controls. A negative control for each secondary antibody was not tested. The
images were captured at 200X magnification. Experiments (N=3) were performed in each trial and
representative images are shown.
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Figures 5.19-5.28: Quantitative real time PCR data of ICA-1T (1μM) treatments for PKC-ι and
Vimentin for melanoma cell lines. Fig. 5.19 and 5.21 represent the amplification plots of PKC-ι
and Vimentin for the SK-MEL-2 cell line. Fig. 5.23 and 5.25 represent the amplification plots of
PKC-ι and Vimentin for the MeWo cell line. Fig. 5.20 and 5.22 represent the melt curve plots of
PKC-ι and Vimentin for the SK-MEL-2 cell line. Fig. 5.24 and 5.26 represent the melt curve plots
of PKC-ι and Vimentin for the SK-MEL-2 cell line. Fig. 5.27 and 5.28 demonstrate the mRNA
level change of PKC-ι and Vimentin for ICA-1T treated MeWo and SK-MEL-2 cell lines,
respectively. The ΔΔCT values were plotted with respect to the mRNA levels of control samples
of each cell line. Statistical significance is indicated by asterisk as *P< 0.05. Experiments (N=3)
were performed in each trial.
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Figures 5.29-5.30: Effects of siRNA knockdown of expression and specific inhibition of PKC-ι on
expression of Vimentin, E-cadherin, PRRX1 and SNAIL1 along with phosphorylation of Vimentin
in melanoma cells (SK-MEL-2 and MeWo). Expression of the protein levels of Vimentin,
phosphorylated Vimentin (S39) and E-cadherin for the siRNA treatment of PKC-ι (20 nM of
siRNA) and PKC-ι specific inhibitor ICA-1T (1 μM) are shown in Fig. 5.29. 60 µg of protein was
loaded in to each well and β-actin was used as the loading control in each Western blot. Fig. 5.30
represents the densitometry values for Western blots in Fig. 5.29. Experiments (N=3) were
performed in each trial and representative bands are shown. Densitometry values are reported as
mean ± SD. Statistical significance is indicated by asterisk as *P≤ 0.05.
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Figures 5.31-5.32: Effects of siRNA knockdown of expression of PRRX1 and SNAIL1 on
expression of PKC-ι, Vimentin and E-cadherin along with phosphorylation of Vimentin and PKCι in melanoma cells (SK-MEL-2 and MeWo). Expression of the protein levels of phosphorylated
PKC-ι, total PKC-ι, Vimentin, phosphorylated Vimentin (S39) and E-cadherin for the siRNA
treatments of PRRX1 and SNAIL1 (30 nM of siRNA against scrambled siRNA) are shown in Fig.
5.31. 60 µg of protein was loaded in to each well and β-actin was used as the loading control in
each Western blot. Fig. 5.32 represents the densitometry values for Western blots in Fig. 5.31.
Experiments (N=4) were performed in each trial and representative bands are shown. Densitometry
values are reported as mean ± SD. Statistical significance is indicated by asterisk as *P≤ 0.05.
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Figures 5.33-5.36: RT-qPCR data of siRNA knockdown of expression of PRRX1 and SNAIL1 on
expression of PKC-ι, Vimentin and E-cadherin in melanoma cell lines (SK-MEL-2 and MeWo).
Fig. 5.33 represents the amplification plots of SNAIL1, PRRX1, PKC-ι, E-cadherin and Vimentin
for the MeWo cell line against β-actin. Fig. 5.34 represents the melt curve plots of SNAIL1,
PRRX1, PKC-ι, E-cadherin, Vimentin and β-actin for the MeWo cell line, showing 6 different
peaks recorded for each target which demonstrate high specificity and accuracy of the targeted
primers. The ΔΔCT values were plotted with respect to the mRNA levels of control samples of
each cell line (Fig. 5.35 for MeWo and Fig. 5.36 for SK-MEL-2). Experiments (N=3) were
performed. Statistical significance is indicated by asterisk as *P≤ 0.05.
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Figure 5.37: PKC-ι associates with Par6 in melanoma cells. Whole cell lysates (100 µg) of
malignant cells (SK-Mel-2 and MeWo) were immunoprecipitated separately for PKC-ι and Par6
using specific antibodies. The first two lanes in Western blot represent the (+) control, which
contained 40 µg of SK-MEL-2 and MeWo whole cell extracts, respectively, applied to ensure that
bands appeared for the specific proteins in Western blots. Western blots of PKC-ι
immunoprecipitation showed an association with Par6. Reverse-immunoprecipitation of Par6
confirmed the association with PKC-ι while no association was observed. Experiments (N = 3)
were performed in each trial.

5.3 Summary
Our results demonstrated the effects of aPKC inhibition on melanoma cell migration and invasion.
ACPD and DNDA treated samples demonstrated a reduction of melanoma motility but it was not
conclusive which aPKC was responsible for upregulating metastasis, since both ACPD and DNDA
inhibit PKC-ι and PKC-ζ. This was solved using specific PKC-ι inhibitors (ICA-1S and ICA-1T)
and a PKC-ζ specific inhibitor ζ-Stat. Migration and invasion were markedly reduced for samples
treated with ICA-1T and ICA-1S compared to ζ-Stat treated samples, suggesting that PKC-ι
inhibition significantly diminishes melanoma cell migration and invasion suggesting that only
PKC-ι is involved in EMT in melanoma. aPKC/Par6 signaling is known to stimulate EMT upon
activation of TGF-β receptors in cancer cells. TGF-β activated aPKC/Par6 stimulates degradation
of RhoA, which leads to the depolymerization of filamentous actin (F-actin) and loss of epithelial
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structural integrity resulting in a reduction of cell-cell adhesion. RhoA is a GTPase, which
promotes actin stress fiber formation thereby maintains cell integrity. Furthermore, TGFβ
upregulates SNAIL1 and PRRX1 TFs that drive genetic reprogramming to facilitate EMT
(215,216). Cells lose E-cadherin while gaining Vimentin during this process. This data showed
that inhibition of PKC-ι using ICA-1T and ICA-1S significantly increased the levels of E-cadherin
and RhoA while decreasing total and phosphorylated Vimentin (S39) and Par6 (142,143). None
of these protein levels were significantly changed as a result of PKC-ζ inhibition. Data also showed
that TGFβ treatments increased the expression of PKC-ι, Vimentin, phosphorylated Vimentin and
Par6 while decreasing E-cadherin and RhoA. These results confirmed the involvement of PKC-ι
in EMT stimulation. IP of PKC-ι confirmed a strong association with Par6 in both melanoma cells
which was confirmed with reverse-IP of Par6 (Fig. 5.37). Previously published reports state that
both aPKCs associate with Par6 and phosphorylate at S345 (217). Interestingly, only PKC-ι
showed an association with Par6, which confirmed that PKC-ι is a major activator of EMT in
melanoma. Moreover, IP of PKC-ι and Vimentin strongly confirmed an association between PKCι and Vimentin. siRNA knockdown of PKC-ι and PKC-ζ, immunofluorescent staining and RTqPCR techniques were also used to study and confirm the association of Vimentin with PKC-ι.
Immunofluorescence staining revealed that the shape of melanoma cells significantly changed
upon inhibition of PKC-ι. Both Vimentin and PKC-ι levels were relatively low in ICA-1T treated
cells in comparison to their respective controls. Furthermore, invasive characteristics such as
formation of lamellipodia, filopodia and invadopodia were distinctively visible in both controls,
though they were not apparent in PKC-ι inhibited cells. Reduction of nuclei volume and cell size,
also confirmed the growth retardation we observed in melanoma cells upon aPKC inhibitor
treatments that resulted in lesser growth in treated cells. As observed in qPCR experiments,
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treatments with PKC-ι specific inhibiors ICA-1T and ICA-1S, depicted a corresponding
downregulation of PKC-ι and suggested that PKC-ι plays a role in its own regulation. This is
further discussed in the next chapter (Chapter 6).
Phosphorylation of Vimentin at S39 is required for its activation, and inhibition of PKC-ι
diminishes this activation process. The reduced levels of total Vimentin observed in Western blots
for ICA-1T and ICA-1S treated cells indicate that without PKC-ι, unphosphorylated Vimentin
undergoes rapid degradation. In addition to activating Vimentin, PKC-ι appears to play a role in
regulating Vimentin expression in some carcinoma cells (210).
As summarized in Figure 5.38, based on these results, we believe that TGFβ stimulated PKCι/Par6/RhoA and Smad2/3 pathways to induce EMT in melanoma through transcriptional activities
of SNAIL1 and PRRX1. Vimentin and PKC-ι activation are upregulated simultaneously to
facilitate EMT in melanoma. PKC-ι activated Vimentin thereby regulates the dynamic changes in
melanoma metastasis. These results further confirm that PKC-ι inhibition using specific inhibitors
such as ICA-1T and ICA-1S not only reduces melanoma cell survival but also negatively affects
the melanoma metastatic progression by downregulating EMT. Taken together, this novel concept
can be used to develop more specific effective therapeutics for melanoma patients based on PKCι being used as a novel biomarker to mitigate melanoma metastasis using specific inhibitors.
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Figure 5.38: A schematic summary of the involvement of PKC-ι in melanoma progression via
activation of EMT and Vimentin. Upon extracellular stimulation with TGFβ, PKC-ι associates and
activates Par6, which stimulates the degradation of RhoA and upregulates EMT. SNAIL1 and
PRRX1 are two very important transcription factors that drive the EMT process by upregulating
Vimentin while downregulating E-cadherin. PKC-ι activates Vimentin by phosphorylation and
initiates disassembly of VIF and facilitates cellular motility. During this process, cadherin
junctions are disrupted as a result of loss of E-cadherin, and β-catenin is translocated to the nucleus
to upregulate the production of facilitating proteins such as CD44, which further stimulate
migration and EMT. Activated Vimentin changes cell polarity to maintain the mesenchymal
phenotype of melanoma cells in-vitro.
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CHAPTER 6
SELF-REGULATION OF PKC-ι IS A CRUCIAL MECHANISM MAKING PKC-ι AN
IMPORTANT NOVEL TARGET IN MELANOMA ANTI-CANCER THERAPEUTICS

6.1 Introduction
So far collected data in the earlier chapters show that PKC-ι serves as an oncogene and therefore
a potential therapeutic target for metastatic melanoma. On the other hand, the data has shown that
PKC-ζ is involved in NF-κB activation and translocation, thereby regulating melanoma cell
survival and growth. However, the data did not illustrate any significant involvement of PKC-ζ in
cellular motility of metastatic melanoma cells. In addition, we showed that PKC-ι plays a crucial
role in the activation of Vimentin increasing the motility of mesenchymal melanoma cells. This
makes PKC-ι overexpression compared to PKC-ζ more lethal in melanoma progression which is
associated with a poor prognosis.
The data confirmed that PKC-ι inhibition using specific inhibitors or the knockdown of its
expression using siRNA significantly induces apoptosis, and reduces the migration and invasion
of melanoma. Interestingly, this data demonstrated that PKC-ι inhibition not only affected the
pathways regulated by PKC-ι, but also downregulated its protein expression on melanoma cells
(Fig. 4.3). The data suggest that PKC-ι plays a role in a self-propagating cycle in melanoma cells,
as observed in some other cycles related to cancer growth, such as TGFβ and CD147 (218). We
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therefore designed further experiments to investigate the role of PKC-ι in its expression regulatory
mechanisms in melanoma cells (144).
Transcription factors (TFs) play a key role in gene expression, controlling the rate of transcription
of genetic information from DNA to messenger RNA by binding to a specific DNA sequence.
Various cytokines often trigger such signaling. In this chapter, we sought to determine which
transcription factors are the main regulators of PKC-ι expression in melanoma cells, giving
emphasis to cytokine stimulation and expression.
We report the effects of the systematic silencing of PKC-ι, NF-κB, c-Jun and FOXO1 on PKC-ι
levels in relation to NF-κB, PI3K/AKT/FOXO1, JNK/c-Jun and signal transducer and activator of
transcription (STAT) signaling, along with cytokine production, to establish the mechanism of
PRKCI (PKC-ι gene) regulation.
The PRKCI gene is located on chromosome 3 (3q26.2), a region identified as an amplicon with
the tendency to undergo replication events (219). To determine TFs which regulate the PRKCI
gene, a specific sequence was selected that includes the PRKCI promoter with a motif feature,
promoter flank and an enhancer. This area provides the optimal platform for TFs to bind to regulate
the transcription. Possible TF bindings were predicted using two different systems: PROMO and
Genomatix Matinspector. Through these, we identified 5 TFs, including FOXO1 and c-Jun. We
systematically silenced these TFs to analyze the downstream effect on PKC-ι expression (144).
The levels of both phosphorylated and total PKC-ι increased upon FOXO1 knockdown by siRNA
and decreased upon the knockdown of c-Jun by siRNA. The results confirmed that c-Jun acts as a
transcriptional activator and that FOXO1 acts as a transcriptional suppressor of PRKCI expression.
Going forward, we establish the roles that these TFs play in an inflammation cycle that governs
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PKC-ι expression and is dependent on PKC-ι for the cycle to continue. Furthermore, we
established that major signaling pathways such as PI3K/AKT/FOXO1 and JNK/c-Jun play a vital
role in regulation of PKC-ι expression. In addition, the cytokines interleukin (IL)-6 and IL-8
promote PKC-ι expression, thereby enhancing NF-κB activity, producing more cytokines as a part
of a cycle such cancers use to develop and spread. IL-17E and intercellular adhesion molecule 1
(ICAM-1) induce FOXO1 to subdue PKC-ι expression. Overall, these results suggest that PKC-ι
plays a central role in melanoma progression with a complex and tightly regulated expression
profile. The specific inhibition of PKC-ι can disrupt its own regulatory cycle, leading to the
disruption of its oncogenic role in melanoma (144).

6.1.1 c-Jun and FOXO1
c-Jun is a TF that combines with activator protein 1 (AP-1) and c-Fos to form an early response
TF complex (220). c-Jun is activated by phosphorylation at S63 and S73 by c-Jun N-terminal
kinases (JNKs), and c-Jun expression is regulated by various extracellular stimuli, such as
cytokines (221). Extracellular signal-regulated kinase (ERK) increases c-Jun transcription (222).
c-Jun is the first discovered oncogenic TF that is associated with metastatic breast cancer, nonsmall cell lung cancer and several other types of cancer (223–225). Phosphorylation at S63 and
S73 activates c-Jun, thereby increasing transcription of c-Jun targeted genes. c-Jun promotes the
oncogenic transformation of ‘ras’ and ‘fos’ in several types of cancer (226,227). Moreover,
FOXO1 regulates gluconeogenesis, insulin signaling and adipogenesis. Phosphorylation plays a
key role in the function of FOXO1 (228,229). AKT phosphorylates FOXO1 at T24, which causes
FOXO1 to drive nuclear exclusion, leading to ubiquitination (230,231). Therefore, the
phosphorylation of FOXO1 is an indication of its downregulation. FOXO1 is a well-known, bona
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fide tumor suppressor (232–234). It plays a regulatory role in both the intrinsic and extrinsic
pathways of apoptosis in many types of cancer, exhibiting an association between FOXO
dysregulation and cancer progression (235,236). Furthermore, the overexpression of FOXO1
decreases cancer cell proliferation and inhibits migration and tumorigenesis. In-vitro and in-vivo
experiments have proven this tumor suppressing activity (237). Importantly, FOXO1 can also be
downregulated by ERK1/2 and PKC-ι, in addition to AKT (234). In the current study, we
demonstrate that, due to PKC-ι inhibition, the availability of active PKC-ι decreases so that it
becomes ineffective at deactivating FOXO1 through phosphorylation. Importantly, this is one of
the direct involvements of PKC-ι in its own expression regulation and PKC-ι inhibition that leads
to continuous upregulation of FOXO1.

6.2 Results
The specific sequence of the PRKCI gene (chromosome 3; 170220768-170225128), which was
selected to contain the promoter, promoter flank, enhancer and a motif feature, was 4,360 bp in
length. The promoter allows TFs to bind and initiate transcription, and the enhancer is a regulatory
region in the flank that facilitates TF binding. We narrowed down possible hits by allowing only
TFs, which can bind within a dissimilarity margin ≤10%, thereby achieving high specificity. We
obtained approximately 70 TF hits to the given target after comparing the outcomes of PROMO
analysis and Genomatix Matinspector. c-Jun, interferon regulatory factor 9 (ISGF3), paired box
gene 3 (PAX3), Early growth response protein 1 (EGR1) and FOXO1 were selected as the top 5
TFs with the highest binding probability to the selected sequence of the PRKCI gene (144).
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FOXO1 and c-Jun stand out as the main transcriptional regulators of PKC-ι expression in
melanoma cells. As shown in Figure 6.1, the results of Western blot analysis revealed that
transfection with each siRNA for EGR1, FOXO1 and c-Jun significantly reduced expression levels
of these proteins. Figure 6.2 illustrates the densitometry analysis for the Western blots on Figure
6.1. The siRNA for EGR1 decreased the expression of EGR1 by 72% (P≤0.05) and 76% (P ≤0.05)
in the SK-MEL-2 and MeWo cells, respectively. The siRNA of FOXO1 decreased the expression
of FOXO1 by 87% (P ≤0.05) and 83% (P ≤0.05), while the levels of phospho FOXO1 (T24)
decreased by 75% (P ≤0.05) and 73% (P ≤0.05) in the SK-MEL-2 and MeWo cells, respectively.
The siRNA of c-Jun decreased the expression of c-Jun by 82% (P ≤0.05) and 73% (P ≤0.05), while
the levels of phospho c-Jun (S73) decreased by 76% (P ≤0.05) and 67% (P ≤0.05) in the SK-MEL2 and MeWo cells, respectively. These results suggested that transfection with each of the siRNAs
knocked down the expression of its respective target. Only the knockdown of FOXO1 and c-Jun
was found to have an effect on the levels of total and phosphorylated PKC-ι (T555) in both cell
lines. The knockdown of FOXO1 by siRNA increased the expression of total PKC-ι by 34% (P
≤0.05) and 24% (P ≤0.05), while it increased the level of phospho PKC-ι (T555) by 28% (P ≤0.05)
and 32% (P ≤0.05) in the SK-MEL-2 and MeWo cells, respectively. The knockdown of c-Jun by
siRNA decreased the expression of total PKC-ι by 17% (P ≤0.05) and 16% (P ≤0.05), and
decreased the level of phospho PKC-ι (T555) by 21% (P ≤0.05) and 17% (P ≤0.05) in the SKMEL-2 and MeWo cells, respectively. The knockdown of the expression of the TFs, ISGF3, EGR1
and PAX3, by siRNA was not found to have a significant effect on the expression of total and
phosphorylated PKC-ι (T555) in both cell lines. Therefore, a decision was made to omit ISGF3,
EGR1 and PAX3, and only FOXO1 and c-Jun were selected for use in the subsequent experiments.
As shown in Figure 6.1, only the EGR1 negative results were included (144).
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Figures 6.1 and 6.2: Effects of RNA interference (siRNA) of the transcription factors of EGR1,
FOXO1 and c-Jun on the expression of PKC-ι and targeted transcription factors in melanoma cells
(SK-MEL-2 and MeWo). Fig. 6.1 shows the expression of the protein levels of phosphorylated
PKC-ι (T555), total PKC-ι, c-Jun, phosphorylated c-Jun (S73), FOXO1, phosphorylated FOXO1
(T24) and EGR1 for the siRNA knockdown of the expression of EGR1, FOXO1 and c-Jun (20 nM
of each siRNA for 48 h) for SK-MEL-2 and MeWo cell lines. Total protein (80 μg) was loaded
into each well and β-actin was used as the internal control in each western blot. Fig. 6.2 shows the
densitometry values for the western blots in 6.1. Experiments (N=4) were performed in each trial
and representative bands are shown. Densitometry values are reported as the means ± SD.
Statistical significance is indicated by an asterisk (*P≤ 0.05).

83

Figures 6.3-6.6: RT-qPCR analysis of siRNA knockdown of FOXO1 and c-Jun for SK-MEL-2
and MeWo cells. mRNA levels of FOXO1, c-Jun, PKC-ι, NF-κB p65 were plotted against β-actin
as the internal control. Fig. 6.3 shows the amplification plots for the targets and melt curves (Fig.
6.4) of the RT-qPCR analysis for tested primers for SK-MEL-2 and MeWo cells, respectively.
Quantitative data for the amplification plots shown in (Fig. 6.5 and 6.6) for the SK-MEL-2 and
MeWo cells, respectively. Experiments (N=3) were performed in each cell lines and the means ±
SD are plotted. Statistical significance is indicated by an asterisk (*P≤ 0.05).
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As shown in qPCR (Fig. 6.3, 6.5 and 6.6), the mRNA level of FOXO1 significantly decreased by
90.8% and 67.3% in the SK-MEL-2 and MeWo cells, respectively, following transfection with
FOXO1 siRNA. The mRNA level of c-Jun significantly decreased by 89.7% and 30.15% in the
SK-MEL-2 and MeWo cells, respectively, following transfection with c-Jun siRNA. These data
confirmed the efficiencies and specificities of the applied siRNAs. The RT-qPCR data revealed
that the PKC-ι mRNA levels decreased (by 47.2%) following transfection with siRNA for c-Jun
in the MeWo cells, even though the PKC-ι levels in the SK-MEL-2 cells were not significantly
altered. On the other hand, the PKC-ι mRNA levels were significantly increased by 23.5% and
42% in the SK-MEL-2 and MeWo cells transfected with FOXO1 siRNA, respectively. Therefore,
these RT-qPCR results agree with the protein expression, which is shown in Figure 6.1. These
results indicate that the downregulation of FOXO1 expression enhances PKC-ι expression, while
the silencing of-Jun expression reduces PKC-ι expression. This indicates that FOXO1
downregulates the expression of PKC-ι and c-Jun upregulates PKC-ι expression in melanoma cells
in-vitro.
FOXO1 holds the key to PKC-ι expression in melanoma cells. As shown in Figures 6.7 and 6.8,
the results of Western blot analysis revealed that the knockdown of the expression of NF-κB by
siRNA significantly decreased the levels of phosphorylated PKC-ι by 23% (P≤0.05) and 18%
(P≤0.05) in the SK-MEL-2 and MeWo cells, respectively. The levels of total PKC-ι significantly
decreased by 14% (P≤0.05) and 12% (P≤0.05) in the SK-MEL-2 and MeWo cells, respectively.
Of note, FOXO1 expression increased by 17% (P≤0.05) and 18% (P≤0.05) in the SK-MEL-2 and
MeWo cells, whereas the levels of phosphorylated FOXO1 decreased in the cells transfected with
NF-κB siRNA. As we have reported previously in Chapter 4, the inhibition of PKC-ι significantly
downregulated the PI3K/AKT pathway, thereby suppressing the activation of AKT.
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Phosphorylated AKT (S473) phosphorylates FOXO1 to cause nuclear exclusion and thereby the
degradation of FOXO1. This explains the elevated levels of active FOXO1 that are due to the
downregulation of phospho AKT upon the downregulation of NF-κB caused by PKC-ι knockdown
by siRNA. As shown in Figures 6.7 and 6.8, silencing NF-κB led to decrease the levels of
phosphorylated AKT (S473) by 13% (P≤0.05) and 11% (P≤0.05) in the SK-MEL-2 and MeWo
cells, respectively. Notably, the levels of phosphorylated c-Jun (S73) and total c-Jun were not
significantly altered upon NF-κB knockdown. Similar results were obtained with NF-κB inhibition
using a well-known NF-κB inhibitor, JSH-23 (100 nM).
Results of enzyme-linked immunosorbent assay (ELISA) confirm an interplay between the
PI3K/AKT, JNK, NF-κB and STAT signaling pathways upon PKC-ι inhibition to coordinate the
regulation of its expression (Fig. 6.9 and 6.10). ICA-1T (1 μM) was used to specifically inhibit
PKC-ι, which allowed to obtain a broad picture of how multiple pathways may influence
melanoma cells in-vitro as a result of PKC-ι inhibition related to PKC-ι regulation. Immuno paired
antibody detection (IPAD) assay is an array-based ELISA allowing the simultaneous detection of
multiple proteins. As shown in Figures 6.9 and 6.10, Caspase-3, CD44 antigen (CD44),
CCAAT/enhancer-binding protein homologous Protein (CHOP), E-cadherin, IκBα, Myc,
NOTCH, phospho eukaryotic translation initiation factor 4E-binding protein 1 (p-4E-BP1)
(T37/46), p-AKT (S473), p-β-catenin (S33/37), p-HER3 (Y1289), phospho insulin receptor
substrate 1 (p-IRS-1) (S1101), phospho jun N-terminal kinase (p-JNK) (T183), p-MEK1
(S217/221), p-mTOR (S2448), p-NF-κB p65 (S536), p-SMAD1 (S463), p-SMAD2 (S465/467),
phospho signal transducer and activator of transcription (p-STAT3) (Y705), p-STAT5 (Y694),
phospho yes-associated protein 1 (p-YAP1) (S127), phospho zeta-chain-associated protein kinase
70 (p-ZAP70) (Y493), cyclin-dependent kinase inhibitor 1 (p21) and PARP levels were reported
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upon ICA-1T treatments against the controls for both cell lines. The caspase-3, E-cadherin, p-NFκB p65 (S536), p-ZAP70 (Y493) and p21 levels significantly increased upon PKC-ι inhibition,
while the CD44, p-4E-BP1 (T37/46), p-AKT (S473), p-IRS-1 (S1101), p-STAT3 (Y705), pSTAT5 (Y694), p-YAP1 (S127) and PARP levels significantly decreased (Fig. 6.9 and 6.10).

Figures 6.7 and 6.8: Effects of RNA interference (siRNA of the transcription factor NF-κB) and
NF-κB inhibitor JSH-23 on the expression of PKC-ι and targeted transcription factors in melanoma
cells (SK-MEL-2 and MeWo). Fig. 6.7 shows protein levels of phosphorylated PKC-ι (T555), total
PKC-ι, NF-κB p65, c-Jun, phosphorylated c-Jun (S73), FOXO1, phosphorylated FOXO1 (T24)
and phosphorylated AKT (S473) for the siRNA knockdown of the expression of NF-κB (20 nM
of each siRNA for 48 h) and JSH-23 treatments (100 nM) for SK-MEL-2 and MeWo cell lines.
Total protein (80 μg) was loaded into each well and β-actin was used as the internal control in each
western blot. Fig. 6.8 shows the representative densitometry values for the western blots in Figure
6.7. Experiments (N=4) were performed in each trial and representative bands are shown.
Densitometry values are reported as the means ± SD. Statistical significance is indicated by an
asterisk (*P≤ 0.05).
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Figures 6.9 and 6.10: Immuno paired antibody detection assay (IPAD) for melanoma cells (SKMEL-2 and MeWo). Fig. 6.9 and 6.10 shows the expression of IPAD assay targets for SK-MEL2 and MeWo cell lines, respectively. Approximately 1x105 cells were cultured in T75 flasks and
24 h post-plating, fresh medium was supplied and the cells were treated with either volume of
sterile water (control) or IC50 concentration of ICA-1T (1 μM). Additional doses were supplied
every 24 h during a 3-day incubation period. The cells were then lysed and prepared lysates with
the final total protein concentration to be >2 μg/ml and then sent them to ActivSignal, LLC facility
to conduct the IPAD assay. IPAD platform is a proprietary multiplexed ELISA technology for
analyzing the activity of multiple signaling pathways in one reaction. Activities of multiple
signaling pathways were monitored simultaneously in a single well through assessing the
expression or protein phosphorylation of 25 target human proteins, such as Caspase-3, CD44,
CHOP, E-cadherin, IκBα, Myc, NOTCH, p-4E-BP1, p-AKT (S473), p-β-catenin, p-HER3, p-IRS1, p-JNK, p-MEK1, p-mTOR, p-NF-κB, p-NUMB, p-SMAD1, p-SMAD2, p-STAT3, p-STAT5,
p-YAP1, p-ZAP70, p21 and PARP. α-tubulin and β-tubulin were used as internal controls in each
trial. Experiments (N=3) were performed in each cell lines and the means ± SD are plotted.
Statistical significance is indicated by an asterisk (*P≤ 0.05).
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Figures 6.11 and 6.12: Cytokine expression analysis of melanoma cells upon PKC-ι knockdown
of expression. Fig. 6.11 shows the Western blot array of the PKC-ι silenced SK-MEL-2 and MeWo
cells against the controls. Fig. 6.12 shows the quantified results of the western blots shown in 6.11
for the SK-MEL-2 and MeWo cells, respectively. IL-6, IL-8, IL-17E, ICAM-1, CXCL-1, CXCL12, GM-SCF, MIF and Serpin were found in detectable levels in western blot analysis for the two
melanoma cell lysates. Experiments (N=3) were performed in each cell lines and the means ± SD
are plotted. Statistical significance is indicated by an asterisk (*P≤ 0.05).
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Figures 6.13-6.16: RT-qPCR analysis of cytokines (IL-6, IL-8, IL-17E and ICAM-1), FOXO1, cJun for PKC-ι siRNA knockdown in SK-MEL-2 and MeWo cells. Fig. 6.13 amplification plots of
the said markers for SK-MEL-2 and MeWo cells, respectively. Fig. 6.14 indicates the melt curves
of the RT-qPCR analysis for tested primers for SK-MEL-2 and MeWo cells, respectively. Fig.
6.15 and 6.16 show the quantitative data for the amplification plots shown in Fig. 6.13.
Experiments (N=3) were performed in each cell lines and the means ± SD are plotted. Statistical
significance is indicated by an asterisk (*P≤ 0.05).
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IL-6, IL-8, IL-17E and ICAM-1 may participate in PKC-ι regulation in an autocrine manner
through transcriptional activation/deactivation. As shown in Figures 6.11 and 6.12, the Western
blot cytokine expression profile for the two melanoma cell lysates exhibited a significant decrease
in the levels of IL-6 and IL-8, while the levels of IL-17E and ICAM-1 increased in the cells
transfected with PKC-ι siRNA (siRNA for PKC-ι, 20 nM) compared to the control (scrambled
siRNA, 20 nM). C-X-C motif chemokine (CXCL)-1, CXCL-12, granulocyte-macrophage colonystimulating factor (GM-SCF), macrophage migration inhibitory factor (MIF) and Serpin were also
found in detectable levels, although these were not significantly altered due to PKC-ι knockdown.
The results of the RT-qPCR analysis of the same lysates are shown in Figure 6.13. Since only IL6, IL-8, IL-17E and ICAM-1 exhibited a significant change in expression upon PKC-ι silencing
by siRNA, they were only tested for those mRNA levels in the RT-qPCR experiments. As
demonstrated in Figures 6.15 for SK-MEL2 and 6.16 for MeWo cell line, RT-qPCR data revealed
how the mRNA levels of PKC-ι significantly decreased by 35.6% and 56.7% in the SK-MEL-2
and MeWo cells, respectively following transfection with PKC-ι siRNA. We observed a
significant decrease in the mRNA levels of both IL-6 and IL-8, with a simultaneous significant
increase in the levels of IL-17E and ICAM-1 upon the knockdown of expression of PKC-ι in both
cell lines. In addition, we found that the FOXO1 mRNA levels increased significantly by 36.1%
and 21.5% in the SK-MEL-2 and MeWo cells, respectively; the c-Jun mRNA levels decreased by
8% and 15.5% in the SK-MEL-2 and MeWo cells, respectively. These data confirm the association
between PKC-ι, FOXO1 and c-Jun presented in Figures 6.1 and 6.3.
Figure 6.17 shows a schematic summary of the regulation of the expression of PKC-ι in melanoma
based on the current and previous data. This model depicts the interactions between NF-κB,
PI3K/AKT/FOXO1, JNK/c-Jun and STAT3/5 signaling pathways during PKC-ι regulation. It is
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shown that PKC-ι plays a very important role in the regulation of its expression through the
transcriptional activation/deactivation of c-Jun and FOXO1. PKC-ι is overexpressed as a result of
c-Jun transcriptional activity with the help of pro-survival, oncogenic PI3K/AKT, NF-κB,
STAT3/5 signaling cascades in melanoma cells. Specific inhibitors of PKC-ι initiates a disruption
to rapid PKC-ι expression cycle where the reduced activity of PKC-ι downregulates the NF-κB
pathway and its transcriptional activity thereby decreases the expression of IL-6 and IL-8. The
activity of AKT decreases as a result of lacking the stimulation from cytokines, such as IL-6, IL8 and TNF-α, which leads to the upregulation of FOXO1, which turns out to be the most important
TF regulating PKC-ι expression after the disruption initiated as a result of PKC-ι inhibition.
FOXO1 negatively regulates the expression of PKC-ι and also diminishes the JNK activity to
retard its activation of c-Jun which serves as the transcription component which upregulates PKCι expression. This process continues and leads to the further downregulation of NF-κB and c-Jun.
Therefore, the upregulation of FOXO1 leads to the continuation of the diminution of PKC-ι
expression. As a result, the total PKC-ι level decreases in melanoma cells. These findings strongly
support our previous data where a reduction in total PKC-ι levels was observed upon the specific
inhibition using PKC-ι inhibitors, such as ICA-1T and ICA-1S.
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Figure 6.17: A schematic summary of the regulation of the expression of PKC-ι in melanoma. This
model depicts the interactions between NF-κB, PI3K/AKT/FOXO1, JNK/c-Jun and STAT3/5
signaling pathways during the PKC-ι regulation. PKC-ι plays an important role in the regulation
of its own expression in an intricate signaling web through c-Jun and FOXO1. PKC-ι is
overexpressed in melanoma cells due to elevated transcriptional activity of c-Jun with the aid of
PI3K/AKT, NF-κB, STAT3/5 signaling. The specific inhibition of PKC-ι initiates a disruption to
rapid PKC-ι expression cycle in melanoma where the reduced activity of PKC-ι downregulates the
NF-κB pathway and its transcriptional activity, which in turn diminishes the expression of IL-6/8.
As a result of this AKT activity reduction, FOXO1 gets upregulated. FOXO1 turns out to be the
most important TF regulating PKC-ι expression after the disruption initiated as a result of PKC-ι
inhibition. Dominant FOXO1 negatively regulates the expression of PKC-ι and also diminishes
the JNK activity to retard its activation of c-Jun. We found c-Jun as the transcription component
that upregulates PKC-ι expression. The downregulation of IL-6 and IL-8 expression leads to the
lessened STAT3/5 signaling, which causes c-Jun transcriptional reduction. This whole process
continues and leads to the further downregulation of NF-κB, AKT and JNK/c-Jun while
upregulating FOXO1, which leads to the continuation of the attenuation of PKC-ι expression. As
a result, the total PKC-ι level decreases in melanoma cells.
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6.3 Summary
On the other hand, our previous data showed that PKC-ι inhibition significantly downregulated
the PI3K/AKT pathway, thereby suppressing the activation of AKT. In this Chapter, we discussed
the mechanism for the downregulation of NF-κB, which reduces the activity of AKT upon PKC-ι
inhibition. PKC-ι inhibition affects FOXO1, as shown by the significantly higher levels of total
FOXO1, while a reduction in its phosphorylated levels was observed, suggesting that NF-κB
downregulation upregulates FOXO1 activity. The elevated levels of FOXO1 negatively influenced
PKC-ι expression and phosphorylation as shown in Figures 6.7 and 6.8 as a result of NF-κB
depletion. This further confirms our previous observations with PKC-ι inhibition with ICA-1T and
ICA-1S (Fig. 4.1), where total PKC-ι, phosphorylated PKC-ι, NF-κB activation and activated AKT
(S473) were significantly reduced. These results could be due to the tight regulation of PKC-ι
expression by FOXO1, which retards PRKCI from transcription. Such results confirmed that
FOXO1 is a major regulator which suppresses the expression of PKC-ι regulation. Of note, the cJun and phosphorylated c-Jun (S63) levels were not significantly altered as a result of NF-κB
siRNA knockdown. This advocates that NF-κB downregulation does not affect PKC-ι expression
through c-Jun. Instead, c-Jun protects cancer cells from apoptosis by cooperating with NF-κB to
prevent apoptosis upon TNF-α stimulation (220). Our data in Chapter 4 showed how TNF-α
upregulates NF-κB, phospho AKT and PKC-ι expression in these two melanoma cell lines (Fig
4.5 and 4.6). However, the data from the current experiment suggest that the TNF-α downstream
target is mainly FOXO1, where it ‘switches off’ through the phosphorylation of elevated AKT.
The inhibition of PKC-ι diminishes this AKT activation, thereby upregulating FOXO1 activity.
On the other hand, our systematic silencing of c-Jun, FOXO1 and EGR1 revealed that (Fig. 6.1
and 6.2 for Westerns blots and 6.3, 6.4 and 6.5 for qPCR) c- Jun also seemed to regulate PKC-ι
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expression, apart from FOXO1. To explain the crosstalk between these cell signaling pathways in
relation to PKC-ι regulation, we conducted two other in-vitro experiments, ELISA using IPAD
assay and a cytokine array. These findings demonstrated links between PKC-ι expression with the
cytokines, IL-6, IL-8, IL-17E and ICAM-1, along with some other key cellular signaling points.
As shown in Figures 6.9 and 6.10, the IPAD ELISA data revealed a significant increase in the
levels of Caspase-3, E-cadherin, p-NF-κB p65 (S536), p-ZAP70 (Y493) and p21 levels upon PKCι inhibition, while the levels of CD44, p-4E-BP1 (T37/46), p-AKT (S473), p-IRS-1 (S1101), pSTAT3 (Y705), p-STAT5 (Y694), p-YAP1 (S127) and PARP levels significantly decreased. We
have already shown in previous Chapters (Chapter 4), using various apoptotic markers, that PKCι inhibition induced the apoptosis of melanoma cells (Fig. 4.1 and 4.3). This is again evident from
increases in the levels of Caspase-3 and the cleavage of PARP in the IPAD assay. Additionally,
PKC-ι inhibition delayed EMT in melanoma and we observed elevated levels of E-cadherin with
downregulation of Vimentin and CD44 expression. Therefore, this IPAD assay provided additional
data for the results we have shown in Chapter 4. Phosphorylation at S536 on the NF-κB p65
transactivation domain is an indication of dimerization of NF-κB subunits. Since PKC-ι inhibition
downregulates NF-κB translocation to the nucleus, phospho NF-κB levels increase in order to
diminish the effect of PKC-ι inhibition. However, elevated FOXO1 does not allow NF-κB to take
over the control since it is missing the crucial assistance needed from PKC-ι due to its inhibition
from ICA-1T and ICA-1S inhibitors. Aberrant STAT3/5 activity has been shown to be connected
to multiple types of cancer (238–243). The cytokines, IL-6 and IL-5, are known to upregulate
STAT signaling, which induces cell survival in many types of cancers (238,239,244). Upregulated
STAT3 increases the transcription of c-Jun (238,245). Our IPAD results indicated that STAT3 and
STAT5 activities were downregulated due to PKC-ι inhibition, suggesting that c-Jun expression
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can be retarded. Few studies, including the one by Hornsveld et al. provided connections between
the JNK pathway and FOXO1, elaborating its tumor suppressing features for weakening JNK
activity (234,246,247). However, JNK activates c-Jun. The data from our Western blot and RTqPCR analysis demonstrated that c-Jun depletion diminished PKC-ι expression, which suggested
that c-Jun acts as an activator of PKC-ι expression. It is therefore evident that both FOXO1 and cJun are involved in regulating PKC-ι expression. The results suggest that FOXO1 plays a major
role over c-Jun only upon PKC-ι inhibition, possibly through multiple mechanisms, such as the
reduction of JNK signaling, retarding PKC-ι expression and cell cycle arrest. Upregulated FOXO1
is well known to induce cell cycle arrest by promoting the transcription of cell cycle kinase
inhibitors or cyclin-dependent kinase inhibitor (CKI). p21 and p27 are two of the most well-known
downstream CKIs induced by FOXOs (234,246). Notably, FOXO1 is also believed to induce
anoikis, which is apoptosis that occurs when cells detach from the extracellular matrix. Our IPADELISA results revealed significantly elevated levels of p21 by approximately 25% in both cell
lines, suggesting that the inhibition of PKC-ι induces cell cycle arrest through FOXO1. This is
another indirect downstream effect of PKC-ι involvement in its expression where inhibition of
PKC-ι enhances FOXO1 anti-tumor activity.
As shown in Figure 6.17, our results summarize that PRKCI expression is negatively regulated by
FOXO1 and positively regulated by c-Jun. When PKC-ι is inhibited, the following series of
downstream effects take place. The downregulation of NF-κB activity decreases the levels of
phospho AKT (S473). As a result of a low activity of AKT along with diminished levels of PKCι, the phosphorylation of FOXO1 is reduced and therefore active FOXO1 (unphosphorylated
FOXO1) levels are being elevated. Elevated FOXO1 suppresses PRKCI gene expression similar
to ‘switch off’ effect. The downregulation of PKC-ι also diminishes STAT3/5 activity, as shown
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by the IPAD assay data. STAT3 and STAT5 are known to upregulate the transcription of c-Jun
and NF-κB (245,248). Therefore, it is evident that PKC-ι inhibition induces the downregulation of
STAT3/5, which decreases the transcription and activation c-Jun. These data suggest that PKC-ι
levels were decreased when c-Jun expression is silenced by siRNA (Fig. 6.1 and 6.2), and as shown
by RT-qPCR in Figures 6.3, 6.5 and 6.6, the knockdown of PKC-ι decreased c-Jun mRNA
expression, but not significantly.
As shown in Figures 6.11 and 6.12, further in-vitro experiments demonstrated changes in cytokine
expression (IL-6, IL-8, IL-17E and ICAM-1) in melanoma cells upon PKC-ι knockdown. As
shown by the results of both Western blot and RT-qPCR analyses, the protein levels of IL-6 and
IL-8 (as well as their mRNA levels) decreased, while the levels of IL-17E and ICAM-1 increased
significantly in both cell lines upon PKC-ι knockdown by siRNA. This suggests that the PKC-ι
self-regulated expression cycle is involved in autocrine signaling. The cellular environment of a
tumor, and in particular melanoma, is frequently exposed to various inflammatory factors and
immune cells. The effect of these factors function to either promote chronic inflammation or
engage in antitumor activity (249). Cytokines are examples of these inflammatory factors; they
play an essential role in regulating tumor microenvironments (250). Cytokines utilize several
signaling pathways to carry out their functions. They act to promote or dysregulate tumor
progression and metastasis. Cytokines, such as CXCL-1, CXCL-12, IL-18, CXCL-10, IL-6 and
IL-8 promote cancer progression by facilitating metastasis. CXCL1, also known as melanoma
growth-stimulatory activity/growth-regulated protein α, is secreted by melanoma cells and is
associated with roles in wound healing, angiogenesis and inflammation. In particular, it has been
linked to tumor formation. High levels of CXCL10/CXCR3 expressed in melanoma have been
linked to metastasis regulation (251). CXCL10 plays an important role in promoting tumor growth
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and metastasis (252). CXCL12, also known as stromal-derived factor-1, utilizes the receptors
CXCR4 and CXCR7. CXCL12 and its receptors have been linked to roles in regulating tumor
metastasis. CXCL-1, CXCL-10, CXCL-12 and IL-18 levels were not significantly altered due to
PKC-ι depletion.
IL-6 is a very important cytokine and contributes to the degradation of IκB-α, leading to the
upregulation of NF-κB translocation. Our data indicated that PKC-ι stimulates NF-κB
translocation through IκB-α degradation. The translocation of NF-κB to the nucleus induces cell
survival through the transcription of various survival factors as well as other cytokines
(104,238,244). IL-8 is an example of such a cytokine. IL-8 plays a role in regulating
polymorphonuclear neutrophil mobilization. In melanoma, IL-8 has been attributed to
extravasation, a key step in metastasis. Studies have shown that the expression of IL-8 in
melanoma is regulated via NF-κB. When NF-κB is translocated to the nucleus, IL-8 expression
increases, leading to the promotion of a more favorable microenvironment for metastasis
(253,254). The results of this study indicated that both IL-6 and IL-8 expression levels decrease
upon transfection with PKC-ι siRNA. As is summarized by the diagram in Figure 6.17, IL-6
expression is regulated by NF-κB, and IL-8 expression is regulated by both NF-κB and STATs.
Our data justified how the PKC-ι inhibition/knockdown downregulates the NF-κB and STAT
signaling pathways. The results suggested that IL-6 and IL-8 play an important role in upregulating
PKC-ι expression, activating c-Jun, while deactivating FOXO1.
Some cytokines promote anti-tumor activity by utilizing an immune response. ICAM-1 plays a
key role in the immune response, including antigen recognition and lymphocyte activation
(255,256). ICAM-1 has been linked to the inhibition of tumor progression through the inhibition
of the PI3K/AKT pathway. The inhibition of this pathway via ICAM-1 exposes tumor cells to
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death via cytotoxic T-lymphocytes (256). Clinical research has also proven that, within the first 5
years of ovarian cancer diagnosis, ICAM-1 expression inhibition is associated with an increased
risk of metastasis (255,256). Another anti-tumor cytokine is IL-17E. IL-17E belongs to a family
of cytokines known as IL-17. In various forms of cancer, including melanoma and pancreatic
cancers, treatment with recombinant IL-17E has been shown to decrease tumor growth (257,258).
The upregulation of IL-17E is linked to the increased expression of TH17 cells. T cells, such as
TH17 have been implicated in the inhibition of tumor-infiltrating effector T cells. The exact
mechanism of IL-17E function in the anti-tumor effect has not been thoroughly explored (259).
Notably, the results of our western blot and RT-qPCR analyses indicated that ICAM-1 and IL-17E
protein and mRNA expression increased upon the silencing of PKC-ι by siRNA. This confirms
that anti-tumor/pro-apoptotic signaling is upregulated upon the knockdown of oncogenic PKC-ι
via an autocrine manner through IL-17E and ICAM-1. Moreover, the results suggest that IL-17E
and ICAM-1 play an important downregulatory role in the regulation of PKC-ι expression along
with FOXO1, opposite to c-Jun, IL-6 and IL-8.
In conclusion, our overall results demonstrate PKC-ι itself to play an important role in its
expression in a complex signaling network through the transcriptional activation/ deactivation of
c-Jun and FOXO1. The reduced activity of PKC-ι due to its specific inhibition, downregulates the
NF-κB pathway and its transcriptional activity, which turns out to ‘strike’ the expression of IL-6
and IL-8. As a result, the activity of AKT decreases, which leads to the upregulation of FOXO1.
FOXO1 is the most important TF regulating PKC-ι expression upon receiving stimulation from
IL-17E and ICAM-1. FOXO1 negatively regulates the expression of PKC-ι, diminishing JNK
activity to retard the activation of c-Jun. IL-6 and IL-8 expression are downregulated via PKC-ιmediated NF-κB transcriptional activity reduction. This leads to STAT3/5 signaling
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downregulation, reducing c-Jun expression. This whole process continues and leads to the further
downregulation of NF-κB, c-Jun and upregulation of FOXO1, which leads to the continuation of
the depletion of PKC-ι expression. As a result of this sequence of events, the total PKC-ι level
decreases in melanoma cells, which began as a result of PKC-ι inhibition. These results indicate
that PKC-ι is being regulated in a rather complex manner, which involves itself as a key
component. PKC-ι inhibition leads to a decrease in its own production, and during this process,
PKC-ι inhibition also triggers multiple anti-tumor/pro-apoptotic signaling. This makes PKC-ι one
of the central key point of interest to specifically target and diminish as a means of treating
melanoma in-vitro. Therefore, our overall results confirm that PKC-ι inhibition using specific and
effective inhibitors, such as ICA-1T and ICA-1S, is significantly effective in the treatment of
melanoma in-vitro. These inhibitors must test against more melanoma cell lines in-vitro and invivo studies must be done in order to solidify the results presented in this dissertation. The current
results strongly suggest that PKC-ι is a prime novel biomarker that can be targeted to design and
develop personalized and targeted therapeutics for melanoma.
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CHAPTER 7
DISCUSSION AND FUTURE DIRECTIONS

7.1 Discussion
Identifying aPKC specific inhibitors is a great challenge due to a largely conserved carboxylterminal catalytic domain among the PKC superfamily as explained in Chapter 1. This similarity
in the kinase domains is the pivotal factor placing them under one parent family. However, the
amino-terminal regulatory domain differs between the subclasses, playing a vital role in secondary
messenger binding, binding to the membrane and protein-protein interactions affecting PKC
activation.
Atypical PKCs were first considered as a novel therapeutic target by Stallings-Mann et al. in 2006
(146). They screened ATM as a potent inhibitor of the interaction between the PB1 domain of
PKC-ι and Par6. ATM, is currently in phase I clinical trial evaluation for lung cancer treatments
and the outcome of the trials are unknown to date. Gunaratne et al. reported that both aPKCs
interact with Par6 and thereby phosphorylate Par6 at S245 (215). This suggested that ATM may
also interact with the complex of Par6 and PKC-ζ. However, Stallings-Mann et al. reported that
ATM demonstrated a specificity on PKC-ι versus PKC-ζ by targeting the interaction between Par6
and PKC-ι (146). The ATM mechanism of action is not fully understood, and in-vitro results
demonstrated off target effects (94,98).
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Blázquez et al. tested calphostin C and chelerythrine against West Nile virus (WNV), in a cell
culture system which significantly inhibit WNV multiplication without affecting cell viability.
They reported that PKCs have also been implicated in different steps during viral replication (260).
Calphostin C and chelerythrine are two wide range PKC inhibitors that target all three PKC classes.
Results indicated that atypical PKCs are involved in WNV multiplication process which can be
effectively retard using said inhibitors (260). Kim et al. reported the application of Echinochrome
A as a cardiomyocyte differentiation agent in mouse embryonic stem cells. They investigated the
potential use of Echinochrome A as an aPKC specific inhibitor and found that IC50 for PKC-ι is
107 μM under in-vitro kinase assay conditions. IC50 values for ICA-1T and ICA-1S were
approximately 1 μM and 2.5μM, respectively. Molecular docking simulation results suggested a
direct binding of Echinochrome A with PKC-ι (261). Another study by Kwiatkowski et al.
identified an azaindole-based scaffold for the development of more potent and specific PKC-ι
inhibitiors (262). They described a fragment based approach and introduced a new class of
potential aPKC inhibitors based on azaindole (262). As indicated in earlier chapters PKC-ι and
PKC-ζ are 84% homologous, make it difficult to identify specific inhibitors. In the current study,
we targeted the amino acid residues 469-475 (glutamine, isoleucine, arginine, isoleucine, proline,
arginine and serine). Data confirms the presence of a potentially druggable allosteric site in the
structure of PKC-ι using the solved crystal structure of PKC-ι. The pocket is located in the C-lobe
of the kinase domain of PKC-ι, which is framed by solvent exposed residues of helices ⍺F-⍺I and
the activation segment. Tested inhibitors were predicted to interact with this site with moderatehigh affinity based on molecular docking. Experimental evidences based on kinase activity assay
for ICA-1S and ICA-1T confirmed the affinity predicted for the identified allosteric site.
Combinations of drugs targeting the ATP binding site and allosteric sites would be expected to
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more effectively inhibit cancer cell growth since it will change the protein dynamics of PKC-ι both
in kinase and regulatory domains. The other important characteristic of this approach is that it
eliminates potential candidates that are capable of binding the ATP binding pocket (which is
conserved between PKC isoforms). The identified allosteric hollow is a potential pocket within
diverse structural elements in PKC-ι and also demonstrated ATP binding did not affect the drug
binding, the predicted specificities were tested in-vitro. Kinase activity studies with MBP as an
aPKC substrate confirmed the molecular docking predictions for their specificity and affinities. ζStat demonstrated a mild activity against PKC-ι at the highest tested concentration (20 μM) and at
the IC50 concentration used, it did not show a significant activity on PKC-ι. Therefore, data
confirmed that ACPD and DNDA target both aPKCs while ICA-1T and ICA-1S target PKC-ι and
ζ-Stat targets PKC-ζ.
Cytotoxicity determinations of the inhibitors to establish their therapeutic potential was very
important. None of the inhibitors demonstrated a significant toxicity to normal melanocytes at the
IC50 concentrations used for two melanoma cell lines. Importantly, all inhibitors displayed
increased cytostatic properties rather than being toxic. These results indicate that inhibitors
effectively arrest melanoma cell growth, differentiation and proliferation before they induce
apoptosis. This confirms that malignant melanoma cells are highly dependent on aPKCs to remain
viable, which was evident as seen by both melanoma cell lines overexpressing aPKCs compared
to the undetectable PKC-ι and low levels of PKC-ζ in normal melanocytes.
Overexpression of aPKCs induces anti-apoptotic effects in many cancers (80,142,143,146).
Apoptosis analysis for inhibitor treatments on melanoma cells demonstrated apoptotic stimulation
upon aPKC inhibition.
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An increase in PARP cleavage and Caspase-3, and a diminution in Bcl-2 all indicate apoptosis
stimulation upon inhibition of both PKC-ι and PKC-ζ. Data showed that both aPKC inhibition
retards the activity of PI3K/AKT mediated NF-κB activation, in which both aPKCs play a role in
releasing NF-κB to translocate to the nucleus and promote cell survival. The data showed that
aPKC inhibition increased the levels of IκB while decreasing the levels of phospho-IκB (S32) and
phospho-IKKα/β (S176/180), confirming that both PKC-ι and PKC-ζ play a role in
phosphorylation of IKKα/β and IκB: increased levels of IκB therefore remain bound to NF-κB
complex and prevent the translocation to the nucleus to promote cell survival. TNF-α stimulation
significantly increased NF-κB levels in both cytosol and nuclei but aPKC inhibition mitigated this
effect significantly. The overall data confirms that both PKC-ζ and PKC-ι are embedded in cellular
survival via NF-κB and PI3K/AKT pathways.
Our in-vitro migration and invasion assays for the two tested human melanoma cell lines
demonstrated that both invasion and migration were markedly reduced by PKC-ι inhibition using
PKC-ι specific inhibitors such as ICA-1T and ICA-1S. Moreover, the data confirmed that PKC-ι
activates Par6 and induced the degradation of RhoA to stimulate the EMT in melanoma cells (Fig.
5.9). Also, IP, immunofluorescence and Western blot techniques demonstrated that PKC-ι strongly
associates with Vimentin and actively participates in the phosphorylation at the S39 position,
which is an important site of Vimentin, essential for Vimentin intermediate filament disassembly
to facilitate increased migration of melanoma cells. Data showed that by inhibiting PKC-ι, the S39
phosphorylation decreases significantly in addition to total Vimentin expression. In addition, upon
PKC-ι diminution we observed cells that are constricted, have a rounded in shape and tend to form
cell colonies, which are all characteristics of epithelial phenotype behavior. However in Vimentinrich mesenchymal conditions, Vimentin wraps around and control the distribution of microtubules
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towards one direction to facilitate rear-front polarity. This is achieved as VIF assembles along
microtubules to form a copy of the previously polarized microtubule network which has a slower
rate of turn over. This is important as the orientation of microtubules is responsible for conferring
the front-rear polarity that is characteristic of mesenchymal cells. Gan et al. showed that disruption
of VIF network on microtubules leads to dramatic changes in the microtubule network and changes
the polarity of cells (263). Ivaska et al. discussed the involvement of PKC-ε on phosphorylation
of Vimentin and control of integrin recycling to facilitate cell motility. Integrins are heterodimeric
cell surface receptors, which mediate cell adhesion and migration via cell to cell and cell to matrix
interactions. Ivaska et al. discuss three major steps in motility; (I) formation of protrusion and new
adhesion sites at leading edge (II) contraction of cell body (III) detachment from trailing end.
Phosphorylation of Vimentin is central in regulation of these dynamics and Vimentin expression
correlates with increased migration following EMT (195). Our data confirms that once PKC-ι is
inhibited both PKC-ι and Vimentin expressions are decreased and E-cadherin expression is
amplified suggesting a slowdown or a possible reversal of the EMT process. Once this happens,
experimental results suggested that the cell shape changes to a more rounded shape and cell form
colonies rather than showing individual mesenchymal behavior as seen in control samples.
As discussed in earlier Chapters, data showed that PKC-ι inhibition significantly downregulated
the PI3K/AKT1 pathway, thereby suppressing the activation of AKT. Downregulation of NF-κB
due to PKC-ι inhibition, results in downregulation of AKT. Data indicates that it increases total
FOXO1 level, while reducing its phosphorylated FOXO1 levels. This suggested that NF-κB
downregulation causes upregulation of FOXO1 activity as a result of PKC-ι inhibition. Therefore
FOXO1 upregulation negatively influences PKC-ι expression and phosphorylation at T555. This
further confirms our previous observations with PKC-ι inhibition with ICA-1T and ICA-1S, where
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total PKC-ι, phosphorylated PKC-ι, NF-κB activation and activated AKT (S473) were
significantly reduced. These results could be due to the tight regulation of PKC-ι expression by
FOXO1, which retards PRKCI transcription. Therefore FOXO1 is a major regulator which
suppresses the expression of PRKCI. Interestingly, c-Jun and phosphorylated c-Jun (S63) levels
were not significantly altered as a result of NF-κB depletion and which suggests that NF-κB
diminution does not affect PKC-ι expression over c-Jun. Instead, c-Jun is known to protect cancer
cells from apoptosis by cooperating with NF-κB signaling to facilitate survival upon TNF-α
stimulation (220). Our data indicated how TNF-α upregulates NF-κB and AKT pathways along
with PKC-ι expression in these two melanoma cell lines. Our data also suggests that the TNF-α
downstream target is mainly FOXO1, where it transcriptionally deactivates through the
phosphorylation of elevated AKT. The inhibition of PKC-ι diminishes this AKT activation,
thereby upregulating FOXO1 activity.
Our data also revealed that c-Jun also plays a role in PKC-ι expression, in addition to FOXO1. The
ELISA results identifies links between PKC-ι expression with the cytokines, IL-6, IL-8, IL-17E
and ICAM-1, along with some other key cellular signaling points such as STAT3/5. ELISA results
revealed a more than two-fold increase of NF-κB p65 (S536) in PKC-ι inhibited samples. This
indicates elevated dimerization of NF-κB subunits prior to its activation in order to accelerate NFκB activation as a result of downstream depletion. Our Western and RT-qPCR data demonstrated
that PKC-ι inhibition downregulates NF-κB translocation to the nucleus therefore phospho NF-κB
levels increase in order to diminish the effect of PKC-ι inhibition. However, elevated FOXO1 does
not allow NF-κB to annex the control since it is missing the essential assistance needed from PKCι due to its inhibition from ICA-1T and ICA-1S inhibitors.
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Elevated STAT3/5 activity is connected to multiple types of cancer (238–241). IL-6 and IL-5 are
known to upregulate STAT signaling, thereby providing survival features in many types of
cancers. Importantly, upregulated STAT3 increases the transcription of c-Jun. Our ELISA results
indicated that STAT3 and STAT5 activities were retarded due to PKC-ι inhibition, leading to cJun diminution. Hornsveld et al. showed that the JNK pathway and FOXO1 cross talk where
FOXO1 provides tumor suppressing features by weakening JNK activity (246). JNK activates cJun by phosphorylation. Western blot and RT-qPCR analysis demonstrated that c-Jun depletion
lessened PKC-ι expression, which suggested that c-Jun acts as an activator of PKC-ι expression.
This confirms that in addition to FOXO1, c-Jun is involved in regulating PKC-ι expression, but in
a promoting manner. These results suggest that FOXO1 plays a dominant role over c-Jun upon
PKC-ι inhibition, possibly through multiple mechanisms, such as the reduction of JNK signaling,
retarding PKC-ι expression and cell cycle arrest. This also explains why apoptosis was stimulated
in melanoma cells as a result of inhibition of PKC-ι in addition to downregulation of the PI3K/AKT
and NF-κB pathways. Overall, FOXO1 is very important in enhancing anti-tumor activities upon
PKC-ι inhibition and it plays the central role of oncogenic PKC-ι depletion.
In conclusion, our overall data suggest that PKC-ι is a major regulatory component responsible for
inducing cell growth, differentiation, survival, migration and invasion while PKC-ζ is mainly
involved in NF-κB signaling to promote cell growth and survival in human melanoma cells. In
addition, PKC-ι is critical for the elevated Vimentin activity thereby driving major cytoskeletal
changes essential for EMT facilitating migration and invasion. Our results also suggest that ICA1T, ICA-1S and ζ-Stat are effective aPKC inhibitors in melanoma cells and do not affect normal
melanocytes at the optimal working concentrations for melanoma cells in-vitro. In addition, ACPD
and DNDA are effective as aPKC inhibitors wherever specific inhibition between PKC-ι and PKC-
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ζ is not essential. These five inhibitors can reduce cell proliferation, migration and invasion, while
inducing apoptosis in SK-MEL-2 and MeWo malignant cell lines. Finally, the evidence we
collected based on the malignant cell lines, indicates PKC-ι and PKC-ζ are potential therapeutic
targets for metastatic melanoma in-vitro.

7.2 Future Directions
The proposed research will address the overarching challenge to revolutionize treatment regimens
by replacing interventions that have life-threatening toxicities with ones that are safe and effective
such as our PKC-ι specific inhibitors. Positive outcomes of in-vivo research will support the invitro data reported here and provide evidence that PKC-ι is a potential novel target for the treatment
of melanoma. The novel concept that PKC-ι may influence melanoma cell proliferation, survival
and motility through discussed pathways is important because it addresses a relationship between
melanoma progression and an oncogene PKC-ι.

(1) Determining the in-vivo effects of ICA-1T, ICA-1S and ζ-Stat on SK-MEL-2-Luc and MeWoLuc xenograft tumors in mice, including tumor growth, cell cycle progression, metastasis,
apoptosis, PKC activity, pathological status and evaluation of pathways in which PKC-ι involves
such as AKT/NF-κB and Par6/RhoA/Smad. These in-vivo results will be helpful to support the invitro data reported in this dissertation.
(2) Establishing the pharmacokinetics, toxicology, structure-activity relationship, off-target effects
of selected inhibitors using in-vivo models. These parameters are essential tools in the pre-clinical
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research setup and therefore need to be performed in order to forward the research from the
benchtop to the clinics.
(3) Studying the effects of combination therapy with these inhibitors using some established
melanoma therapeutics such as BRAF inhibitors. This will be helpful to optimize the effects and
concentrations, dose, etc. in order to achieve best possible outcomes of anti-aPKC therapeutics.
(4) Studying the impact of aPKC inhibition of other cancer types such as prostate, breast, lung,
glioblastoma, kidney etc. both in-vitro and in-vivo to investigate the role of aPKCs in cancer
progression and to develop a generalize concept of aPKC activities in cancer thereby promoting
the importance of aPKC inhibition in cancer research.
(5) Studying the regulatory mechanism of PKC-ζ in melanoma cells both in-vitro and in-vivo in
order to gain better knowledge of how these two similar proteins transcriptionally regulate at
different conditions.
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CHAPTER 8
MATERIALS AND METHODS

8.1 Materials
ICA-1 nucleotide (ICA-1T) and nucleoside (ICA-1S) were synthesized by Therachem (Jaipur,
India). ACPD (Product # R426911) was purchased from Sigma Aldrich (St. Louis, MO, USA).
DNDA (NSC6082) and ζ-Stat (NSC37044) were obtained from the National Institutes of Health,
(NIH) (Bethesda, MD, USA). They were dissolved in sterile distilled water (vehicle) prior to use.
Antibodies were purchased as follows with the applied concentrations: PKC-ι (610175, 1:2000)
and Bcl-2 (610538, 1:500) from BD Biosciences (San Jose, CA, USA) and PKC-ζ (sc-17781,
1:1000), NF-kB p65 (sc-372-G, 1:1000), IκBα (sc-1643, 1:500), phospho IκBα (sc-8404, 1:400)
and Caspase-3 (sc-7272, 1:1000), from Santa Cruz Biotechnology (Santa Cruz, CA, USA);
phospho PKC-ζ (PA5-17837, 1:500), E-Cadherin (701134, 1:1000), Vimentin (MA3-745,
1:1000), Myelin basic protein (MBP) (PA1-10008, 1:500) and phospho PKC-ι (44-968G, 1:500)
from Thermo Fisher Scientific (Waltham, MA, USA); early growth response protein 1 (EGR1;
4153S, 1:500), c-Jun (9165S, 1:400), phospho c-Jun (3270S, 1:250), FOXO1 (2880S, 1:500),
phospho FOXO1 (9464S, 1:400), phospho AKT (4059S, 1:500), phospho Vimentin (13614S,
1:500), SNAIL1 (3879S, 1:400), phospho PTEN (9551, 1:1000), phospho IκKα/β (2697, 1:500),
PARP (9532, 1:1000) and cleaved-PARP (9185, 1:1000) from Cell Signaling Technology
(Danvers, MA, USA); and β-actin peroxidase (A3854, 1:4000) from Sigma-Aldrich (St. Louis,
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MO, USA); CD44 (ab97478, 1:2000), RhoA (ab54835, 1:1000), PRRX1 (ab211292, 1:500) and
β-catenin (ab16051, 1:2000) from Abcam (Cambridge, UK). Phospho MBP (Thr 125, 1:400)
(Catalog # 05-429) from EMD Millipore (Billerica, MA). Enhanced chemiluminescence solution
(34080) was purchased from Pierce (Rockford, IL, USA). Dulbecco’s phosphate-buffered saline
without Mg2+ and Ca2+ (D8537) and Trypsin–EDTA (ethylenediaminetetraacetic acid) solution
(T4049) were purchased from Sigma-Aldrich. Human small interfering RNA (siRNA) for PKC-ι
(SR303741), PKC-ζ (303747), EGR1 (SR301358), c-Jun (SR302499), FOXO1 (SR301618) paired
box gene 3 (PAX3; SR303360), interferon regulatory factor 9 (IRF9; SR307030), SNAIL
(SR304489), and NF-κB p65 (SR321602) were purchased from Origene Technologies Inc.
(Rockville, MD, USA) and siRNA for PRRX1 (AM16708) was purchased from Thermo Fisher
Scientific. The NF-κB specific inhibitor, 4-methyl-N1-(3-phenylpropyl)-1,2-benzenediamine
(JSH-23) (J4455) was purchased from Sigma-Aldrich. 4-[3-(4-iodophenyl)-2-(4-nitropheny))-2H5-tetrazolio]-1,3-benzene disulfonate (WST-1) reagent for cell proliferation (11644807001) was
purchased from Roche Diagnostics (Mannhelm, Germany). Basement membrane extraction
(BME) (3455-096-02) was purchased from Trevigen (Gaithersburg, MD, USA). Human
recombinant proteins PKC-ι (PV3183), PKC-ζ (P2273), TNFα (10602HNAE25), TGFβ1
(PHG9204) and MBP (MBS717422) were purchased from Thermo Fisher Scientific and
MyBioSource (San Diego, CA, USA) respectively.

8.2 Molecular docking
ICA-1T, ICA-1S, and ζ-Stat were docked on solved crystal structures of PKC-ι with and without
bound ATP (PDB 3A8W, 3A8X) using the molecular docking program AutoDock Vina (264).
The three dimensional compound structures were translated from SMILES string to protein data
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bank (PDB) file using the NCI/CADD translator (https://cactus.nci.nih.gov/translate/) (265).
SWISS-MODELs of PKC-ζ were generated using the human PKC-ζ sequence (UniProt Q05513)
and the crystallized PKC-ι structures as templates. Modeled PKC-ζ structures were processed for
geometric minimization using Phenix (v 1.11.1-2575). Ligands and PKC structures were prepared
for docking using AutoDockTools 1.5.6 (9_17_14 build). Molecular docking was performed using
AutoDock Vina 1.1.2 (May 11, 2011 build). Top scoring docked ligand conformations, ranked by
lowest kcal/mol scores coupled with visual inspections, were then selected for localized Vina
screening. Docking output files were visualized with, and molecular images generated using
Pymol (v 1.7.2.1). All molecular docking tasks were performed on a high performance workstation
running Linux. Molecular docking for ACPD and DNDA was performed using homologous
models for PKC-ι and PKC-ζ as described in Pillai, et al. (99).

8.3 Cells and cell culture
The SK-MEL-2 (ATCC® HTB68™), MeWo (ATCC® HTB65™) melanoma cell lines and
primary epidermal normal melanocyte cell line (ATCC® PCS-200-013™) were purchased from the
American Type Tissue Culture Collection (ATCC; Rockville, MD, USA). MEL-F-NEO normal
melanocyte cell line was purchased from Zen-Bio, Inc. (Research Triangle Park, NC, USA). All
cells were frozen in liquid nitrogen immediately with early passages with “Gibco Recovery” cell
culture freezing medium from Thermo Fisher Scientific (12648010). The cells of passages 2 to 5
were resuscitated from liquid nitrogen and cultured for <3 months before re-initiating culture from
the same passage for each tested experiment. The ATCC and Zen-Bio Inc. authenticated the cell
lines using morphology, karyotyping and PCR-based approaches (266). All cell lines were cultured
at 37 °C and 5% CO2. Dermal cell basal medium (PCS-200-030) with melanocyte growth kit (PCS112

200-042) were used for PCS-200-013 and melanocyte growth medium (MEL-2) was used for
MEL-F-NEO cell culturing according to the respective instruction manual. Eagle's minimum
essential media- EMEM (90% v/v) with fetal bovine serum-FBS (10% v/v) and Penicillin (5
µg/mL) were used for SK-MEL-2 and MeWo cell culturing. All cell lines were seeded and grown
as monolayers in T25 or T75 flasks.

8.4 Western blot analysis
The Bradford protein assay was used to measure the protein concentrations of extracted cell lysates
in each experiment (inhibitor treatments or siRNA treatments). Total protein (40-80 μg) was
loaded into each well measuring the equivalent volumes of the cell lysates, separated by 10% SDSPAGE and electro-blotted onto supported nitrocellulose membranes. Western blot separation and
Transferring processes were carried out in an ice cold environment in a chamber filled with ice.
At the same time, both running buffer and transfer buffer were kept in 4°C to maintain the low
temperature prior to use. Each blot was blocked for 1 h with 4.5% bovine serum albumin (BP1600100, Thermo Fischer Scientific) in TBST solution (0.1% V/V Tween in 1X TBS) at room
temperature (approximately 25°C). Protein bands were probed with each targeted primary
antibody at 4°C overnight followed by horseradish-peroxidase-conjugate anti-mouse or anti-rabbit
secondary antibody for 2 h at room temperature. Immuno-reactive bands were visualized with
enhanced chemiluminescence solution (34080) according to the manufacturer’s instructions
(Pierce Inc., Rockford, IL, USA). Goat anti-mouse IgG (170-6516) and goat anti-rabbit IgG (1706515) secondary antibodies were used from Bio-Rad Laboratories (Hercules, CA, USA).
Manufacturer’s recommended concentrations were used for all tested primary and secondary
antibodies. β-actin was used as the internal control in each Western blot.
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8.5 PKC activity assay
PKC activity assay was conducted by monitoring the phosphorylation of MBP (0.025 mg/ml), a
known substrate for PKCs. The detailed procedure was performed as described in Pillai, et al. for
all five inhibitors (0.1 to 10/20 μM) on recombinant PKC-ι and PKC-ζ (0.01 μg/μl) (99). Samples
then fractionated by SDS-PAGE and immunoblotted for phosphorylated MBP. Kinase activity was
calculated based on the densitometry values of Western blots.

8.6 Inhibitor dose response curves and WST-1 assay for cell viability and cytotoxicity
PCS-200-013, MEL-F-NEO, SK-MEL-2 and MeWo cells (4 × 104) were cultured in T25 flasks
and treated with either an equal volume of sterile water (vehicle control) or inhibitors using a series
of concentrations (0.1-10 μM). The detailed procedure was performed as described in Pillai, et al.
for all five inhibitors on recombinant PKC-ι and PKC-ζ (0.01 μg/μL) using a series of inhibitor
concentrations (0-10 μM) (99).
WST-1 assay was performed by culturing approximately 4 × 103 cells/well (PCS-200-013, MELF-NEO, SK-MEL-2 and MeWo) in a 96 well plate. After 24 h post plating time, fresh media were
supplied (200 µl/well) and treated with either an equal volume of sterile water (vehicle control) or
with the IC50 concentrations of ACPD (2.5 μM), DNDA (2.5 μM), ICA-1T (1 µM) or ICA-1S (2.5
µM) or ζ-Stat (5 µM). These IC50 values were obtained based on the dose response curves.
Additional doses were supplied every 24 h during a 3 day incubation period. At the end of 3 day
treatment, media were removed and fresh media (100 µL) were added with WST-1 reagent (10
µL) to each well. The absorbance was measured at 450 nm for every 1 h up to 10 hours using the
Synergy HT microplate reader from Biotek (Winooski, VT, USA).
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8.7 Wound healing assay cell migration
The detailed procedure was performed for SK-MEL-2 and MeWo cells as described in Justus, et
al. (267). Cells were treated with either sterile water or inhibitors to achieve respective IC 50
concentrations and plates were incubated at 37°C and 5% CO2. Photographs of wound closure
were taken utilizing a Motic AE31E microscope with Moticam BTU8 Tablet (40× magnification)
at 24 h intervals for 3 days and analyzed using “ImageJ” image processing program (National
Institutes of Health, Rockville, MD, USA).

8.8 Basement membrane extract (BME) assay for cell invasion
This in-vitro invasion assay was performed for SK-MEL-2 and MeWo cells as described in
Feoktistova, et al. using BME (0.2×) as the inner coating of transwell plate (268). Cells were
treated with either sterile water or inhibitors to achieve respective IC50 concentrations and plates
were incubated at 37°C and 5% CO2 for 3 days. At the end of the 3rd day, crystal violet (0.5%) was
used to stain the cells adhered to the bottom surface of the membrane in transwell insert to visualize
the inhibition of invasion. Photographs of the stained cells were taken from Motic AE31E
microscope with Moticam BTU8 Tablet (100× magnification) after washing the extra stains
remained in the transwell plate. Subsequently, 70% Ethanol (200 μl) was added to dissolve crystal
violet and absorbance was measured at 590 nm.
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8.9 Immunofluorescence microscopy
SK-MEL-2 and MeWo cells were plated in chamber slides (154461, Thermo Fisher Scientifics)
and treated with either sterile water or inhibitors to achieve respective IC50 concentration of ICA1T. Slides were incubated at 37°C and 5% CO2 for 3 days. At the end of the 3rd day, cells were
prepared as described in El Bassit, et al. (269) and stained for PKC-ι (ab5282 anti-rabbit polyclonal
primary antibody 1:200 and A21206 anti-rabbit secondary antibody at 1:1000; green) and for
Vimentin (MA3-745 anti-mouse monoclonal primary antibody at 1:40 and A32727 anti-mouse
secondary antibody at 1:1000; red) to visualize under the Nikon Mirco-FX fluorescence
microscope with Jenoptik D-07739 Jena camera (200× magnification). 4′,6-diamidino-2phenylindole (DAPI) in Gold Antifade Mountant (S36938; blue) was used to visualize the nucleus.

8.10 Identification of possible transcription factors (TFs) which bind to the PRKCI gene
The PRKCI gene sequence was obtained from ensemble.org (ENSG00000163558) which locates
in chromosome 3 from bp170222365-170305981 (3q26.2) (270,271). The forward strand
sequence was used and compared with EPD/Eukaryotic Promoter Database (https://epd.vitalit.ch/index.php) for its promoter sequence. A specific sequence was then selected (chromosome 3;
170220768-170225128); the sequence contains the promoter, promoter flank, enhancer and a motif
feature. This sequence predicted possible TFs that can bind within a dissimilarity margin ≤10%
using PROMO, which is a virtual laboratory for studying transcription factor binding sites in DNA
sequences (http://alggen.lsi.upc.es/). TF targets were then compared with the Genomatix
Matinspector results to generate the final TF list for the following experiments.
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8.11 Knockdown of TFs, PKC-ι and NF-κB gene expression by siRNA
Each siRNA contained a pool of three combined RNA sequences for the targeted gene and
respective control siRNA contained a scrambled sequence, which did not lead to specific
degradation of any known cellular messenger RNA and whose sequence is a proprietary of Origene
Technologies Inc. The experiments performed with siRNA are as follows: Approximately 1x105
cells (SK-MEL-2 and MeWo) were cultured in T25 flasks and at 24 h post-plating, fresh medium
was supplied and the cells were treated with a 20 nM concentration of one of the transcription
factor siRNAs or scrambled siRNA as a control using ‘siTran’ siRNA transfection reagent
(TT300002) from Origene Technologies, Inc. according to the manufacturer’s recommended
ratios. After 48 h of the post-treatment period, cells were subsequently lifted and cell lysates were
collected with cell lysis buffer (C7027, Invitrogen/Thermo Fisher Scientific). Western blot
analysis was performed as previously described in the study by Win, et al. (80).

8.12 Immunoprecipitation and Western blot analysis
Approximately 1 × 105 cells (SK-MEL-2 and MeWo) were cultured in T75 flasks and 24 h post
plating, fresh media were supplied and cells were treated with either an equal volume of sterile
water or IC50 concentration of the tested inhibitor. Additional doses were supplied every 24 h
during a 3 day incubation period. Cells were then lifted using Trypsin and the cell lysates were
collected either with cell lysis buffer (Catalog # C7027, Invitrogen) or IP lysis buffer (Catalog #
87788, Thermo Fisher). For the IP, the cell lysates were collected in the same way and 200 μg of
total protein from each lysate was immunoprecipitated using primary antibody of interest (either
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PKC-ι or Vimentin) and analyzed using Western blots after separated by SDS-PAGE. The Western
blots were performed as described in 8.4.

8.13 Densitometry
The intensity of western blot bands was measured using ‘Image Studio Lite 5.x’software
developed by LI-COR Biosciences (Lincoln, NE, USA) in which the background intensity was
subtracted from the intensity of each band to obtain the corrected intensity of the proteins.

8. 14 Analysis of cytokine expression using enzyme-linked immunosorbent assay (ELISA)
An ELISA containing a cytokine array (Cat. no. ARY005B) was obtained from R&D Systems
(Minneapolis, MN, USA). Approximately 1x105 cells (SK-MEL-2 and MeWo) were cultured in
T25 flasks and at 24 h post-plating, fresh medium was supplied and the cells were treated with a
20 nM concentration of PKC-ι siRNA or scrambled siRNA as a control. After 48 h of the posttreatment period, the cells were subsequently lifted, lysed, processed and analyzed according to
manufacturer’s instructions using cytokine array kit reagents. Total protein (100 μg) from each
sample was used to expose the membranes and chemoluminescence photographs as Western blots
were taken to analyze the cytokine expression profiles of the melanoma cells upon PKC-ι siRNA
knockdown.
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8.15 Immunopaired antibody detection assay (IPAD)
Approximately 1x105 cells were cultured in T25 flasks and at 24 h post-plating, fresh medium was
supplied and the cells were treated with either volume of sterile water (control) or the IC 50
concentration of ICA-1T (1 μM). Additional doses were supplied every 24 h during a 3-day
incubation period at 37°C. The cells were then lysed and lysates were prepared with the final total
protein concentration being >2 μg/ml and then delivered to ActivSignal, LLC (Natick, MA, USA)
for further processing and analyzing. The ActivSignal IPAD platform is a multiplex ELISA-based
proprietary technology for analyzing the activity of multiple signaling pathways in one reaction
with high sensitivity and specificity. The activities of >20 signaling pathways were monitored
simultaneously in a single well through assessing the expression or protein phosphorylation of 70
target human proteins.

8.16 Reverse transcription-quantitative PCR (RT-qPCR)
qPCR was performed on RNA isolated from SK-MEL-2 and MeWo cell lysates collected after
siRNA treatments for PKC-ι, c-Jun and FOXO1 against scrambled siRNA as the control. Total
RNA was isolated from the cell pellets using RNA lysis buffer which comes with the RNeasy mini
kit (74104) from Qiagen (Germantown, MD, USA). RNA was reverse transcribed into cDNA with
You-Prime First Strand Beads (27-9264-01) form GE healthcare UK Ltd. (Buckinghamshire, UK).
qPCR was performed on cDNA using the QuantStudio3 Real-Time PCR system (Thermo Fisher
Scientific).

Gene

expression

CACACTTTCCAAGCCAAGCG
(primers:

Forward,

was
and

observed
reverse,

for

PKC-ι

Forward,

GGCGTCCAAGTCCCCATATT),

GTGCCGAAAAAGGAAGCTGG
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(primers:

and

c-Jun
reverse,

CTGCGTTAGCATGAGTTGGC),

FOXO1

(primers:

Forward,

ATGGCTTGGTGTCTTTCTTTTCT and reverse, TGTGGCTGACAAGACTTAACTCAA), IL17E

(primers:

Forward,

GCCACCACTCCTGTCTCTTC

and

reverse,

CCAGGGGCTCTTTCTTCTCC), IL-6 (primers: Forward, GCTCCCTACACACATGCCTT and
reverse,

CCTTCCCTGTGCATGGTGAT),

IL-8

(primers:

Forward,

CAGAGACAGCAGAGCACAC and reverse, ATCAGGAAGGCTGCCAAGAG) and ICAM-1
(primers:

Forward,

GGGAACAACCGGAAGGTGTA

and

reverse,

CAGTTCCACCCGTTCTGGAG). β-actin (primers: Forward, AGAGCTACGAGCTGCCTGAC
and reverse, AGCACTGTGTTGGCGTACAG) was used as an internal control. PCR reactions
used SYBR-Green PCR Mix (Applied Biosystems, Foster City, CA, USA). cDNA was denatured
at at 95°C for 10 min, followed by 40 cycles of denaturing at 95°C for 20 sec and an annealing
stage of 65°C for 40 sec. QuantStudio Software 2.0 was used to quantify gene expression using 2ΔΔCT

(Thermo Fisher Scientific) as explained by Livak and Schmittgen (272).

8.17 Statistical analysis
All data are presented as the means ± SD. Statistical analysis was performed with one- or two-way
ANOVA followed by Tukey’s HSD test as a multiple comparisons test using the ‘VassarStats’
web tool for statistical analysis. P-values ≤0.05 or ≤0.01 were considered to indicate statistically
significant differences.
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APPENDIX A
The results demonstrated in this dissertation were published in the form of three full research
articles and one book chapter. Publishers granted permissions to reproduce those contents and the
emails, letters of permission granting are included in this section.
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APPENDIX B
Full Western blots of the bands in Figure 2.1.
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APPENDIX C
Full Western blots of the bands in Figure 4.1.
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Full Western blots of the bands in Figure 4.3.
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Full Western blots of the bands in Figure 4.5
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APPENDIX D
Full Western blots of the bands in Figure 5.9
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Full Western blots of the bands in Figure 5.11
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Full Western blots of the bands in Figure 5.13
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Full Western blots for the bands in Figure 5.15.
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Full Western blots for the bands in Figure 5.29.
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Full Western blots for the bands in Figure 5.31.
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APPENDIX E
Full Western blots for the bands in Figure 6.1.
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Full Westerns blots for the Figure 6.7.
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